WO2003097625A1 - Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use - Google Patents

Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use Download PDF

Info

Publication number
WO2003097625A1
WO2003097625A1 PCT/US2003/002675 US0302675W WO03097625A1 WO 2003097625 A1 WO2003097625 A1 WO 2003097625A1 US 0302675 W US0302675 W US 0302675W WO 03097625 A1 WO03097625 A1 WO 03097625A1
Authority
WO
WIPO (PCT)
Prior art keywords
och
crι
carbon atoms
alkyl
cell binding
Prior art date
Application number
PCT/US2003/002675
Other languages
French (fr)
Inventor
Ravi V. J. Chari
Michael Louis Miller
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Priority to AU2003210731A priority Critical patent/AU2003210731C1/en
Priority to CA2485424A priority patent/CA2485424C/en
Priority to JP2004505358A priority patent/JP2005533026A/en
Priority to EP03752980A priority patent/EP1506181A4/en
Publication of WO2003097625A1 publication Critical patent/WO2003097625A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel cytotoxic agents with enhanced water solubility and their therapeutic uses. More specifically, the invention relates to novel cytotoxic agents that are taxanes which comprise both a polyethylene glycol moiety that enhances water solubility and a means of chemical linkage to a cell binding agent. These taxanes can be chemically linked to cell binding agents to provide therapeutics that are delivered to specific cell populations in a targeted manner.
  • Cytotoxic drugs such as methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, calicheamicin and maytansinoids have been conjugated to a variety of murine monoclonal antibodies.
  • the drug molecules were linked to the antibody molecules through an intermediary carrier molecule such as serum albumin (Garnett et al, 46 Cancer Res. 2407-2412 (1986); Ohkawa et al, 23 Cancer Immunol. Immunother. 81-86 (1986); Endo et al, 47 Cancer Res. 1076-1080 (1980)), dextran (Hurwitz et al, 2 Appl. Biochem.
  • Taxanes are mitotic spindle poisons that inhibit the depolymerization of tubulin, resulting in an increase in the rate of microtubule assembly and cell death. While docetaxel and paclitaxel are useful agents in the treatment of cancer, their antitumor activity is limited because of their non-specific toxicity towards normal cells.
  • One object of the present invention is to provide novel taxanes that incorporate a polyethylene glycol moiety that confers enhanced aqueous solubility.
  • Another object of the present invention is to provide polyethylene glycol- containing taxanes that are highly cytotoxic in vitro and that can still be effectively used in the treatment of many diseases.
  • a taxane comprising a polyethylene glycol-containing linking group at C-7 or C-10, the linking group being capable of linking the taxanes to a cell binding agent or other chemical moiety.
  • the invention also provides a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes.
  • the present invention also provides a therapeutic composition
  • a therapeutic composition comprising an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and (B) A pharmaceutically acceptable carrier, diluent, or excipient.
  • the present invention also provides a method of killing selected cell populations comprising contacting the target cells or tissue containing target cells with a cytotoxic amount of the above-described cytotoxic agent.
  • Figure 1 is a chemical formula that represents structures of various taxanes, including some of the more potent taxanes described in U.S. Patents 6,340,701 and
  • Figure 2 is a chemical formula that represents structures of some of the polyethylene glycol-containing taxanes according to the present invention.
  • Figure 3 shows the structure of 10-deacetylbaccatin III, which is the starting material for preparing the taxanes of the present invention and the structure of the parent taxoid.
  • Figures 4-8 show the synthetic schemes for the preparation of polyethylene glycol-containing taxanes of the present invention.
  • Figures 9, 10 and 11 show the in vitro cytotoxicity of polyethylene glycol- containing taxanes according to the present invention.
  • This invention is based on the synthesis of novel taxanes that retain high cytotoxicity and that can be linked effectively to cell binding agents. It has previously been shown that the linkage of highly cytotoxic drugs to antibodies using a cleavable link, such as a disulfide bond, ensures the release of fully active drug inside the cell, and such conjugates are cytotoxic in an antigen specific manner (RN.J. Chari et al, 52 Cancer Res. 127-131 (1992); USP 5,475,092; and USP 5,416,064, 6,340,701 and 6,372,738). However, the art reveals that it is extremely difficult to modify drugs to improve their aqueous solubility without eliminating their cytotoxic potential.
  • the disclosed invention overcomes this problem by modifying the disclosed taxanes with chemical moieties, and especially ones containing polyethylene glycol groups, to which appropriate cell binding agents can be linked.
  • the disclosed novel taxanes have greater water solubility along with higher cytotoxic potency than that of known taxanes.
  • the cell binding agent-taxane conjugates permit the full measure of the cytotoxic action of the taxanes to be applied in a targeted fashion against unwanted cells only, therefore, avoiding side effects due to damage to non-targeted healthy cells.
  • This invention facilitates the linkage of taxanes to cell binding agents in aqueous media which had previously been difficult.
  • the invention provides useful agents for the elimination of diseased or abnormal cells that are to be killed, lysed, or destroyed, such as tumor cells (particularly solid tumor cells), virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells (cells that produce autoantibodies), activated cells (those involved in graft rejection or graft vs. host disease), or any other type of diseased or abnormal cells, while exhibiting a minimum of side effects.
  • the cytotoxic agent according to the present invention comprises one or more polyethylene glycol-containing taxanes linked to a cell binding agent via a linking group.
  • the linking group is part of a chemical moiety that is covalently bound to a taxane through conventional methods.
  • the chemical moiety can be covalently bound to the taxane via a disulfide linkage.
  • taxanes useful in the present invention may have the formula (I) shown below:
  • novel taxanes of the invention can be divided into two embodiments, (1) and (2) based on the position of the PEG substituent bearing a linking group.
  • Ri can be H, an electron withdrawing group, such as F,
  • R and R 7 are the same or different and each can be H, linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms, or simple or substituted aryl having
  • R 8 can be linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
  • R ⁇ and R 7 are each H or are alkyl or aryl groups having 1 to 4 carbon atoms.
  • Examples of preferred -NR 6 R groups include dimethyl amino, diethyl amino, dipropyl amino, and dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl.
  • Ri is preferably OMe, OEt, CI, F, NO 2 , or CF 3 .
  • Ri is in the meta position and Ri' is OMe, and R
  • R can be -OC(CH 3 ) 3 or -C 6 H 5 .
  • R 2 is a PEG-containing linking group and R 5 can be H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula -CNR] 0 R ⁇ , wherein R 10 and R ⁇ are the same or different and can be H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl.
  • preferred examples include -COCH 3 -COCH 2 CH 5 and -COCH 2 CH 2 CH 3 .
  • preferred examples include -CONHCH 2 CH 3> -CONHCH 2 CH 2 CH 3 , -CO-morpholino, -CO-piperazino, -CO- piperidino, or -CO-N-methylpiperazino.
  • R 5 is a PEG-containing linking group and R 2 can be H or can have the same definition as above for R 5 for embodiment (1)
  • Suitable linking groups are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups. Preferred are disulfide groups and thioether groups.
  • the side chain carrying the thiol or disulfide group can be linear or branched, aromatic or heterocyclic.
  • the taxane is linked to the polyethylene glycol through the hydroxyl group on the taxane.
  • the hydroxyl group is used to form, for example, an ether, ester, or carbamate to link to one end of the polyethylene glycol.
  • the moiety that contains the thiol- or disulfide group is linked to the other end of the polyethylene glycol.
  • This linking moiety will contain, for example, an ether, ester, amide or carbamate.
  • suitable side chains Specific examples of the thiol- or disulfide- containing side chains include:
  • Ri3 M ⁇ (OCH 2 C ⁇ 2) 1 ,0(C R,3Ri4) ⁇ (CH2) r dilemma(CR,3Ri4) ⁇ SZ, -CO(C R 13 R 14 ),(CH 2 ) m (C R13R14).
  • X is a linear alkyl or branched alkyl having 1-10 carbon atoms
  • R and R 12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl or heterocyclic, and R 12 can in addition be H, [38] R ⁇ 3 and R 14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl, [39] 1 is 0 or an integer from 1 to 10,
  • m is an integer of 1 to 10
  • n 2 to 1000.
  • Examples of linear alkyls include methyl, ethyl, propyl, butyl, pentyl and hexyl.
  • Examples of branched alkyls include isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and 1-ethyl-propyl.
  • Examples of cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Examples of simple aryls include phenyl and naphthyl.
  • substituted aryls include aryls such as those described above substituted with alkyl groups, with halogens, such as CI, Br, F, nitro groups, amino groups, sulfonic acid groups, carboxylic acid groups, hydroxy groups or alkoxy groups.
  • heterocyclics are compounds wherein the heteroatoms are selected from O, N, and S, and include morpholino, piperidino, piperazino, N- methylpiperazino, pyrrollyl, pyridyl, furyl and thiophene.
  • the taxanes of the present invention that have a PEG-containing thiol- or disulfide-containing substituent are in themselves novel.
  • the taxanes that have a PEG-containing thiol or disulfide-containing substituent can be synthesized according to known methods.
  • the starting material for the synthesis is the commercially available 10-deacetylbaccatin III, shown in Figure 3.
  • the chemistry to introduce various substituents is described in several publications (Ojima et al, J.Med. Chem.39, 3889-3896, (1996), Ojima et al., 40 J. Med. Chem. 267-278 (1997); I. Ojima et al., 96 Proc. Natl. Acad. Set, 4256-4261 (1999); I. Ojima et al., USP 5,475,011 and USP 5,811,452).
  • the substituent Ri on the phenyl ring and the position of the substituent Ri can be varied until a compound of the desired toxicity is obtained. Furthermore, the degree of substitution on the phenyl ring can be varied to achieve a desired toxicity. That is, the phenyl ring can have one or more substituents (e.g., mono-, di-, or tri- substitution of the phenyl ring) which provide another means for achieving a desired toxicity.
  • High cytotoxicity is defined as exhibiting a toxicity having an IC 50 in the range of 1 x 10 "12 to 3 x 10 "9 M, when measured in vitro with cultured cancer cells upon a 72 hour exposure time to the drug.
  • One of ordinary skill in the art can determine the appropriate chemical moiety for Rj and the appropriate position for Ri using only routine experimentation.
  • the disulfide or thiol-containing substituent can be incorporated into the PEG group that is introduced by reaction at the one of the hydroxyl substituents in the taxane skeleton.
  • the chemistry to protect the various hydroxyl groups, while reacting the desired one, has been described previously (see, for example, the references cited supra).
  • the substituent is introduced by simply converting the free hydroxyl group to a PEG-containing ether, a PEG-containing ester, or a PEG-containing carbamate. This transformation is achieved as follows.
  • the desired hydroxyl group is deprotonated by treatment with the commercially available reagent lithium hexamethyldisilazane (1.2 equivalents) in tetrahydrofuran at -40°C as described in I. Ojima et al, supra.
  • the resulting alkoxide anion is then reacted with halogenated PEG bearing an appropriately protected thiol substituent, followed by deprotection of the thiol group to provide the desired thiol-containing PEGylated taxane.
  • the thiol group can be converted into a methyl or pyridyl disulfide by reaction with methyl methane thiolsulfonate or dithiodipyridine respectively. This method is described in USP 5,416,064.
  • the desired hydroxyl group can be esterified directly by reaction with a carboxy-PEG bearing a disulfide-containing substituent, in the presence of a coupling agent such as di-isopropylcarbodiimide (DIC), to provide a disulfide-containing PEGylated taxane ester. Reduction of the disulfide substituent can then provide the thiol-containing PEGylated taxane ester.
  • a commercially available chloroformate such as para-nitrophenyl chloroformate
  • Representative synthetic schemes are shown in Figures 4 to 8 and the methods are described in Example 2.
  • Disulfide-containing and thiol-containing PEGylated taxane drugs of the invention can be evaluated for their ability to suppress proliferation of various unwanted cell lines in vitro.
  • cell lines such as the human lung carcinoma line A549, the human breast tumor line MCF-7, and the Burkitt's lymphoma line Namalwa can easily be used for the assessment of cytotoxicity of these compounds.
  • Cells to be evaluated can be exposed to the compounds for 72 hours and the surviving fractions of cells measured in direct assays by known methods. IC 50 values can then be calculated from the results of the assays. Results from the testing of PEGylated taxoids of this invention are shown in Figures 9, 10, and 11.
  • PEGylated taxoid 17 is extremely potent with an IC 50 value of 6.3 x 10 "1 ' M towards MCF-7 cells.
  • Pegylated taxoid 20 is also highly potent, with an IC 50 value of 3.2 x 10 '10 M towards MCF-7 cells.
  • Cell binding agents may be of any kind presently known, or that become known and include peptides and non-peptides.
  • the cell-binding agent may be any compound that can bind a cell, either in a specific or nonspecific manner. Generally, these can be antibodies, or fragments thereof (especially monoclonal antibodies), lymphokines, hormones, growth factors, vitamins, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance.
  • cell binding agents that can be used include:
  • -interferons e.g. ⁇ , ⁇ , ⁇
  • -lymphokines such as IL-2, IL-3, IL-4, IL-6;
  • -hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens;
  • -vitamins such as folic acid
  • EGF EGF
  • TGF- ⁇ TGF- ⁇
  • VEGF vascular endothelial growth factor
  • PDGF PDGF, FGF, IGF-1, IGF-2, Somatostatin, G-CSF, M-CSF and GM-CSF (Burgess, 5 Immunology Today 155-158 (1984)); and
  • Monoclonal antibody techniques allow for the production of extremely specific cell binding agents in the form of specific monoclonal antibodies or fragments thereof.
  • Particularly well known in the art are techniques for creating monoclonal antibodies, or fragments thereof, by immunizing mice, rats, hamsters, or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
  • Sensitized human cells can also be used.
  • Another method of creating monoclonal antibodies, or fragments thereof is the use of phage libraries of sFv (single chain variable region), specifically human sFv. (See e.g., Griffiths et al., USP 5,885,793; McCafferty et al., WO 92/01047; Liming et al., WO 99/06587).
  • the monoclonal antibody MY9 is a murine IgGi antibody that binds specifically to the CD33 Antigen (J.D. Griffin et al 8 Leukemia Res., 521 (1984)) and can be used if the target cells express CD33 such as in the disease of acute myelogenous leukemia (AML).
  • the monoclonal antibody anti-B4 is a murine IgGi, that binds to the CD 19 antigen on B cells (Nadler et al, 131 J. Immunol.
  • the target cells are B cells or diseased cells that express this antigen, such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia.
  • the antibody N901 is a murine monoclonal IgGi antibody that binds to CD56 found on small cell lung carcinoma cells and on cells of other tumors of neuroendocrine origin (Roy et al. J. Nat. Cancerlnst. 88:1136-1145 (1996)).
  • GM-CSF which binds to myeloid cells
  • IL-2 which binds to activated T-cells can be used for prevention of transplant graft rejection, for therapy and prevention of graft- versus-host disease, and for treatment of acute T-cell leukemia.
  • MSH which binds to melanocytes, can be used for the treatment of melanoma.
  • Folic acid which targets the folate receptor expressed on ovarian and other cancers, is also a suitable cell binding agent.
  • Cancers of the breast and testes can be successfully targeted with estrogen (or estrogen analogues) or androgen (or androgen analogues), respectively, as cell binding agents.
  • Conjugates of the PEGylated taxanes of the invention and a cell binding agent can be formed using any techniques presently known or later developed. Numerous methods of conjugation are taught in USP 5,416,064 and USP 5,475,092.
  • the PEGylated taxane ester can be modified to yield a free amino group and then linked to an antibody or other cell binding agent via an acid labile linker or a photolabile linker.
  • the PEGylated taxane ester can be condensed with a peptide and subsequently linked to a cell binding agent to produce a peptidase labile linker.
  • the hydroxyl group on the PEGylated taxane ester can be succinylated and linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free drug.
  • the PEGylated taxane ethers, esters, or carbamates are treated to create a free or protected thiol group, and then the disulfide- or thiol-containing taxanes are linked to the cell binding agent via disulfide bonds.
  • conjugates of the invention are antibody-PEGylated-taxane, antibody fragment-PEGylated-taxane, epidermal growth factor (EGF)-PEGylated-
  • taxane melanocyte stimulating hormone (MSH)-PEGylated-taxane, (IGF-1)- PEGylated-taxane, (IGF-2)-PEGylated-taxane, (Somatostatin)-PEGylated-taxane, thyroid stimulating hormone (TSH)-PEGylated-taxane, estrogen-PEGylated-taxane, estrogen analogue-PEGylated-taxane, androgen-PEGylated-taxane, androgen analogue-PEGylated-taxane, and folate-PEGylated-taxane.
  • PEGylated-taxane conjugates of antibodies, antibody fragments, protein or peptide hormones, protein or peptide growth factors and other proteins are made in the same way by known methods.
  • peptides and antibodies can be modified with cross linking reagents such as N-succinimidyl 3-(2- pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate
  • SPP 4-succinimidyl-oxycarbonyl- ⁇ -methyl- ⁇ -(2-pyridyl dithio)-toluene
  • SDPB ⁇ -succinimidyl-3-(2-pyridyldithio) butyrate
  • 2-iminothiolane or S-acetylsuccinic anhydride by known methods. See, Carlsson et al, 173 Biochem. J. 723-737 (1978); Blattler et al, 24 Biochem. 1517-1524 (1985); Lambert et al, 22 Biochem. 3913-3920 (1983); Klotz et al, 96 Arch. Biochem. Biophys. 605 (1962); and Liu et al, 18 Biochem.
  • the free or protected thiol-containing cell binding agent thus derived is then reacted with a disulfide- or thiol-containing taxane to produce conjugates.
  • the conjugates can be purified by HPLC or by gel filtration.
  • estrogen and androgen cell binding agents such as estradiol and androstenediol can be esterified at the C-17 hydroxy group with an appropriate disulfide containing carboxylic acid using e.g., dicyclohexylcarbodiimide as a condensing agent.
  • carboxylic acids that can be employed are 3-(2-pyridyldithio) propanoic acid, 3-methyldithiopropanoic acid, 4-(2-pyridyldithio) pentanoic acid, and 3-phenyldithiopropanoic acid.
  • Esterification of the C-17 hydroxy group can also be achieved by reaction with an appropriately protected thiol group containing carboxylic acid chloride such as 3-S-acetylpropanoyl chloride. Other methods of esterification can also be employed as described in the literature (Haslam, 36 Tetrahedron 2409-2433 (1980)).
  • the protected or free thiol containing androgen or estrogen can then be reacted with a disulfide- or thiol-containing PEGylated taxane to produce conjugates.
  • the conjugates can be purified by column chromatography on silica gel or by HPLC.
  • Folic acid can be condensed with a suitable hydrazide such as 4-(2-pyridyldithio) pentanoic acid hydrazide in the presence of a condensing agent such as dicyclohexyl carbodiimide to give a hydrazone containing an active disulfide.
  • a suitable hydrazide such as 4-(2-pyridyldithio) pentanoic acid hydrazide
  • a condensing agent such as dicyclohexyl carbodiimide
  • the disulfide-containing folate can then be reacted with a thiol-containing taxane to produce a conjugate that can be purified by column chromatography over silica gel or by HPLC
  • monoclonal antibody- or cell binding agent-PEGylated-taxane conjugates are those that are joined via a disulfide bond, as discussed above, that are capable of delivering the PEGylated taxane molecules.
  • Such cell binding conjugates are prepared by known methods such as by modifying monoclonal antibodies with succinimidyl pyridyl-dithiopropionate (SPDP) (Carlsson et al, 173 Biochem. J. 723- 737 (1978)). The resulting thiopyridyl group is then displaced by treatment with thiol-containing PEGylated taxanes to produce disulfide linked conjugates.
  • SPDP succinimidyl pyridyl-dithiopropionate
  • the formation of the cell binding conjugate is effected by direct displacement of the aryl-thiol of the PEGylated taxane by sulfhydryl groups previously introduced into antibody molecules.
  • Conjugates containing 1 to 10 taxane drugs linked via a disulfide bridge are readily prepared by either method.
  • a solution of the dithiopyridyl modified antibody at a concentration of 1 mg/ml in 0.1 M potassium phosphate buffer, at pH 6.5 containing 1 mM EDTA is treated with the thiol-containing PEGylated taxane (1.7 molar eq./ dithiopyridyl group).
  • the release of thiopyridine from the modified antibody is monitored spectrophotometrically at 343 nm and is complete in about 20 hours.
  • the antibody-taxane conjugate is purified and freed of unreacted drug and other low molecular weight material by gel filtration through a column of Sephadex G-25 or Sephacryl S300.
  • the number of taxane moieties bound per antibody molecule can be determined by measuring the ratio of the absorbance at 230 nm and 275 nm. An average of 1-10 taxane molecules/antibody molecule can be linked via disulfide bonds by this method.
  • Antibody-PEGylated taxane conjugates with non-cleavable links can also be prepared.
  • the antibody can be modified with crosslinking reagents such as succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate (SMCC), sulfo-SMCC, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), sulfo-MBS or succinimidyl-iodoacetate, as described in the literature, to introduce 1-10 reactive groups.
  • crosslinking reagents such as succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate (SMCC), sulfo-SMCC, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), sulfo-MBS or succinimidyl-iodoacetate, as described in the literature, to introduce 1-10 reactive groups.
  • the modified antibody is then reacted with the thiol-containing taxane derivative to produce a conjugate.
  • the conjugate can be purified by dialysis, or by gel filtration through a Sephadex G-25 or Sephacryl S-300 column.
  • the modified antibodies, or fragments thereof, are treated with the thiol-containing PEGylated taxanes (1.25 molar equivalent/maleimido group). The mixtures are incubated overnight at ambient temperature.
  • the antibody-taxane conjugates are purified by dialysis, or by gel filtration through a Sephadex G-25 or Sephacryl S-300 column. Typically, an average of 1 to 10 taxanes per antibody are linked.
  • a prefe ⁇ ed method is to modify antibodies, or fragments thereof, with succinimidyl-4-(maleimidomethyl)-cyclohexane-l-carboxylate (SMCC) to introduce maleimido groups followed by reaction of the modified antibody or fragment with the thiol-containing PEGylated taxanes to give a thioether linked conjugate.
  • SMCC succinimidyl-4-(maleimidomethyl)-cyclohexane-l-carboxylate
  • Cytotoxicity of the PEGylated taxanes and their antibody conjugates to non- adherent cell lines can be measured by back- extrapolation of cell proliferation curves as described in Goldmacher et al, 135 J. Immunol. 3648-3651 (1985). Cytotoxicity of these compounds to adherent cell lines such as SKBR3 and A431 can be determined by clonogenic assays as described in Goldmacher et al, 102 J. Cell Biol. 1312-1319 (1986).
  • the present invention also provides a therapeutic composition comprising:
  • the present invention provides a method of killing selected cell populations comprising contacting the target cells or tissue containing target cells with a cytotoxic amount of the above-described cytotoxic agent.
  • cytotoxic agent is prepared as described above.
  • Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of ordinary skill in the art as the clinical situation warrants.
  • suitable carriers, diluents and/or excipients include: (1 )
  • the method for killing selected cell populations can be practiced in vitro, in vivo, or ex vivo.
  • Examples of in vitro uses include treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells; treatments of bone ma ⁇ ow prior to their transplantation in order to kill competent T cells and prevent graft- versus-host-disease (GVHD); treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen or to kill variants that express undesired antigen.
  • GVHD graft- versus-host-disease
  • Examples of clinical ex vivo use are to remove tumor cells or lymphoid cells from bone marrow prior to autologous transplantation in cancer treatment or in treatment of autoimmune disease, or to remove T cells and other lymphoid cells from autologous or allogenic bone marrow or tissue prior to transplant in order to prevent GVHD.
  • Treatment can be carried out as follows. Bone marrow is harvested from the patient or other individual and then incubated in medium containing serum to which is
  • concentrations range from about 10 ⁇ M to 1 pM, for about 30 minutes to about 48 hours at about 37°C.
  • concentration and time of incubation i.e., the dose, are readily determined by one of ordinary skill in the art.
  • the bone marrow cells are washed with medium containing serum and returned to the patient intravenously according to known methods.
  • the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
  • the cytotoxic agent of the invention will be supplied as a solution or a lyophihzed powder that are tested for sterility and for endotoxin levels.
  • suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 4 weeks as an intravenous bolus each week. Bolus doses are given in 50 to 100 ml of normal saline to which 5 to 10 ml of human serum
  • albumin can be added. Dosages will be 10 ⁇ g to 2000 mg per administration,
  • intravenously range of 100 ng to 20mg/kg per day. After four weeks of treatment, the patient can continue to receive treatment on a weekly basis.
  • Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by one of ordinary skill in the art as the clinical situation warrants.
  • Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any type including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, and lymphatic organs; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc.; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and others as determined by one of ordinary skill in the art.
  • EXAMPLE 1 IN VITRO CYTOTOXICITY ASSAYS [86]
  • the sulfide, disulfide, and sulfhydryl containing PEGylated taxane drugs of the invention can be evaluated for their ability to suppress proliferation of various human tumor cell lines in vitro.
  • Namalwa (Burkitt's lymphoma) are used for the assessment of cytotoxicity of these compounds. Cells are exposed to the compounds for 72 hours and the surviving fractions of cells are measured in direct assays. (A549 and MCF-7 are assayed for plating efficiency (Goldmacher et al, 102 J. Cell. Biol. 1312-1319 (1986) and
  • Namalwa are assayed by growth back extrapolation (Goldmacher et al, 135 J.
  • Tetrahydrofuran was dried by distillation over sodium metal.
  • Dimethylactamide and dimethylformamide were dried by distillation over calcium hydride under reduced pressure. All other solvents used were reagent grade or HPLC grade.
  • the reaction was diluted with 10 mL of 20% ethyl acetate in hexane and passed through a short pad of silica gel using 200 mL of the same solution to wash the silica, and the resulting filtrate was concentrated.
  • the crude residue obtained was purified on a silica gel column using 40% ethyl acetate in hexane as the eluant to give 4 as a white solid, which contained small amounts of DCC and acid.
  • the product was used without further purification. A small sample was purified the
  • Disulfide Links The conjugation of thiol-containing PEGylated taxanes to antibodies, or fragments thereof, via disulfide links is performed in two steps.
  • dithiopyridyl groups are introduced into antibodies or antibody fragments using succinimidyl pyridyldithiopentanoate (SPP) as described by Carlsson et al.
  • SPP succinimidyl pyridyldithiopentanoate
  • the thiopyridyl groups are then displaced by reaction with the thiol-containing taxane to produce a conjugate.
  • the release of thiopyridine from the modified antibody or fragment thereof is monitored spectrophotometrically at 343 nm and is found to be complete in about 20 hours.
  • the antibody-taxane conjugate is purified and freed of unreacted drug and other low molecular weight material by gel filtration through a column of Sephadex G-25.
  • the number of taxane molecules bound per antibody molecule is determined by measuring the ratio between the absorbances at 230 nm and 275 nm. An average of 1-10 taxane molecules per antibody molecule can be linked via disulfide bonds by this method.
  • Noncleavable Thioether Link The conjugation of a thiol-containing PEGylated- taxane is performed in two steps.
  • the antibody, or fragment thereof, is first reacted with succinimidyl maleimidomethylcyclohexane carboxylate (SMCC) to introduce maleimido groups.
  • SMCC succinimidyl maleimidomethylcyclohexane carboxylate
  • the modified antibody is then reacted with the thiol-containing PEGylated taxane forming thioether links.
  • Antibodies, anti-B4, MY9, anti-EGF receptor and N901, or fragments thereof, are modified with SMCC as described in the literature. [Ill] The modified antibodies or antibody fragments are treated with thiol-containing taxane (1.25 molar equivalent/maleimido group). The mixtures are
  • PEGylated Taxanes can be esterified with N-protected amino acids, such as
  • N-tboc-L-alanine in the presence of dicyclohexyl-carbodiimide and dimethylaminopyridine (DMAP) by standard methods described in the chemical literature. Cleavage of the t-boc protecting group with trifluoroacetic acid will give a taxane ester containing a terminal amino group. This amino group containing taxane can be linked to antibodies, or fragments thereof, and other cell binding agents via an acid labile linker as previously described (Bla tler et al, 24 Biochemistry, 1517-1524
  • Photolabile Linker [113] The amino group-containing PEGylated taxane derivative described above can be linked to cell binding agents via a photolabile linker as previously described.
  • amino group-containing PEGylated taxane described above can also be linked to cell binding agents via peptide spacer linkers. It has been previously shown that short peptide spacers between drugs and macromolecular protein carriers are stable in serum but are readily hydrolyzed by intracellular lysosomal peptidases
  • the amino group containing taxane can be condensed with peptides such as Ala-Leu, Leu-Ala-Leu or a dimer of Ala-Leu using condensing agents such as l-[3-(dimethylamino)propyl]-3- ethyl carbodiimide-HCl to give a peptide derivative of the taxane which can then be linked to cell binding agents.
  • PEGylated Taxanes can be esterified by reaction of the hydroxyl group with succinic anhydride and then linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free drug. (For examples see:

Abstract

A cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more polyethylene glycol-containing taxanes linked to a cell binding agent.

Description

CYTOTOXIC AGENTS COMPRISING POLYETHYLENE GLYCOL- CONTAINING TAXANES AND THEIR THERAPEUTIC USE
FIELD OF THE INVENTION
[01] The present invention relates to novel cytotoxic agents with enhanced water solubility and their therapeutic uses. More specifically, the invention relates to novel cytotoxic agents that are taxanes which comprise both a polyethylene glycol moiety that enhances water solubility and a means of chemical linkage to a cell binding agent. These taxanes can be chemically linked to cell binding agents to provide therapeutics that are delivered to specific cell populations in a targeted manner.
BACKGROUND OF THE INVENTION
[02] Many reports have appeared which are directed to the tageting of tumor cells with monoclonal antibody-drug conjugates (Sela et al, in Immunoconjugates, pp. 189- 216 (C. Nogel, ed. 1987); Ghose et al, in Targeted Drugs, pp. 1-22 (E. Goldberg, ed. 1983); Diener et al, in Antibody Mediated Delivery Systems, pp. 1-23 (J. Rodwell, ed. 1988); Pietersz et al, in Antibody Mediated Delivery Systems, pp. 25-53 (J. Rodwell, ed. 1988); Bumol et al, in Antibody Mediated Delivery Systems, pp. 55-79 (J. Rodwell, ed. 1988), G.A. Pietersz and K.Krauer, 2 J. Drug Targeting, 183-215 (1994), RN.J. Chari, 31 Adv. Drug Delivery Revs., 89-104 (1998), W.A. Blattler and RN.J. Chari, in Anticancer Agents, Frontiers in Cancer Chemotherapy, 317-338, ACS Symposium Series 796, 1. Ojima et al eds, American Chemical Society 2001). Cytotoxic drugs such as methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, calicheamicin and maytansinoids have been conjugated to a variety of murine monoclonal antibodies. In some cases, the drug molecules were linked to the antibody molecules through an intermediary carrier molecule such as serum albumin (Garnett et al, 46 Cancer Res. 2407-2412 (1986); Ohkawa et al, 23 Cancer Immunol. Immunother. 81-86 (1986); Endo et al, 47 Cancer Res. 1076-1080 (1980)), dextran (Hurwitz et al, 2 Appl. Biochem. 25-35 (1980); Manabi et al, 34 Biochem. Pharmacol. 289-291 (1985); Dillman et al, 46 Cancer Res. 4886-4891 (1986); Shoval et al, 85 Proc. Natl. Acad. Sci. U.S.A. 8276- 8280 (1988)), or polyglutamic acid (Tsukada et al, 73 J. Natl. Cane. Inst. 721-729 (1984); Kato et al, 27 J. Med. Chem. 1602-1607 (1984); Tsukada et al, 52 Br. J. Cancer 111-116 (1985). [03] A wide array of linkers is now available for the preparation of such immunoconjugates, including both cleavable and non-cleavable linkers. In vitro cytotoxicity tests, however, have revealed that antibody-drug conjugates rarely achieve the same cytotoxic potency as the free unconjugated drugs. This suggested that mechanisms by which drug molecules are released from conjugated antibodies are very inefficient. Early work in the area of immunotoxin conjugates showed that conjugates formed via disulfide bridges between monoclonal antibodies and catalytically active protein toxins were more cytotoxic than conjugates containing other linkers. See, Lambert et al, 260 J Biol. Chem. 12035-12041 (1985); Lambert et al, in Immunotoxins 175-209 (A. Frankel, ed. 1988); Ghetie et al, 48 Cancer Res. 2610-2617 (1988). This improved cytotoxicity was attributed to the high intracellular concentration of reduced glutathione contributing to the efficient cleavage of the disulfide bond between the antibody molecule and the toxin. Maytansinoids and calicheamicin are the first examples of highly cytotoxic drugs that have been linked to monoclonal antibodies via disulfide bonds. Antibody conjugates of these drugs have been shown to possess high potency in vitro and exceptional antitumor activity in human tumor xenograft models in mice (RN.J. Chari et al., 52 Cancer Res., 127-131 (1992), C. Liu et al., 93, Proc. Natl. Acad. Sci., 8618-8623 (1996), L.M. Hinman et al., 53, Cancer Res., 3536-3542 (1993), P.R. Hamann et al, 13, BioConjugate Chem., 40-46 (2002)).
[04] One reason for the lack of disulfide linked antibody-drug conjugates is the unavailability of cytotoxic drugs possessing a sulfur atom containing moiety that can be readily used to link the drug to an antibody via a disulfide bridge. Furthermore, chemical modification of existing drugs is difficult without diminishing their cytotoxic potential.
[05] In spite of the above described difficulties, useful cytotoxic agents comprising cell binding moieties and the group of cytotoxic drugs known as maytansinoids have been reported (USP 5,208,020, USP 5,416,064, and R. N. J. Chari, 31 Advanced Drug Delivery Reviews 89-104 (1998)). Similarly, useful cytotoxic agents comprising cell binding moieties and analogues and derivatives of the potent antitumor antibotic CC-1065 have also been reported (USP 5,475,092 and USP 5,585,499).
[06] Paclitaxel (Taxol®), a cytotoxic natural product, and docetaxel (Taxotere®), a semi-synthetic derivative (See Figure 1), are widely used in the treatment of cancer. These compounds belong to the family of compounds called taxanes. Taxanes are mitotic spindle poisons that inhibit the depolymerization of tubulin, resulting in an increase in the rate of microtubule assembly and cell death. While docetaxel and paclitaxel are useful agents in the treatment of cancer, their antitumor activity is limited because of their non-specific toxicity towards normal cells. [07] Further, compounds like paclitaxel and docetaxel themselves are not sufficiently potent to be used in conjugates of cell binding agents. Recently, a few new taxanes with greater potency than either docetaxel or paclitaxel have been prepared (Figure 1). In addition, these taxanes bear a suitable functionality that allows linkage via a cleavable bond to cell binding agents (U.S. Patents 6,340,701 and 6,372,738). However, these taxanes display poor aqueous solubility. Thus linkage to cell binding agents, which are typically only soluble in water, necessitates the use of a high percentage of an organic co-solvent which could lead to damage of the cell binding agent. Thus, conjugation reactions with cell-binding agents currently have to be performed in extremely dilute aqueous solutions.
[08] One approach commonly used to enhance the aqueous solubility of poorly soluble drugs such as paclitaxel is to convert them into prodrugs by incorporating a polyethylene glycol spacer of varying chain lengths, in a process often called PEGylation. These prodrugs are inactive or poorly active in vitro, and have to rely on in vivo enzymatic cleavage of the polyethylene glycol group to be activated. Such in vivo cleavage mechanisms are inefficient resulting in poor conversion into active drug. In addition, these PEGylated-taxanes do not have a linking group that allows for conjugation to cell binding agents (USP 5,614,549; (5,648,506; 5,880,131; 5,824,701; R.B. Greenwald et al., 60, J. Org. Chem., 331-336 (1995), R.B. Greenwald et al., 39, J Med. Chem., 424-431 (1996), A.E. Matthew et al., 35, J. Med. Chem., 145-151 (1992)).
[09] Accordingly, a method of providing taxanes that contain a polyethylene glycol moiety that confers enhanced aqueous solubility, while preserving cytotoxic potency, without the need for additional in vivo activation is required. These PEGylated taxanes must also possess a linking group that allows for linkage with cell binding agents. Thus, a method of using these taxanes for treating diseases wherein their side effects are reduced without compromising their cytotoxicity is greatly needed.
SUMMARY OF THE INVENTION
[10] One object of the present invention is to provide novel taxanes that incorporate a polyethylene glycol moiety that confers enhanced aqueous solubility.
[11] Another object of the present invention is to provide polyethylene glycol- containing taxanes that are highly cytotoxic in vitro and that can still be effectively used in the treatment of many diseases.
[12] These and other objects have been achieved by providing a taxane comprising a polyethylene glycol-containing linking group at C-7 or C-10, the linking group being capable of linking the taxanes to a cell binding agent or other chemical moiety.
[13] The invention also provides a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes.
[14] The present invention also provides a therapeutic composition comprising an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and (B) A pharmaceutically acceptable carrier, diluent, or excipient.
[15] The present invention also provides a method of killing selected cell populations comprising contacting the target cells or tissue containing target cells with a cytotoxic amount of the above-described cytotoxic agent. BRIEF DESCRIPTION OF THE DRAWINGS
[16] Figure 1 is a chemical formula that represents structures of various taxanes, including some of the more potent taxanes described in U.S. Patents 6,340,701 and
6,372,738
[17] Figure 2 is a chemical formula that represents structures of some of the polyethylene glycol-containing taxanes according to the present invention. [18] Figure 3 shows the structure of 10-deacetylbaccatin III, which is the starting material for preparing the taxanes of the present invention and the structure of the parent taxoid. [19] Figures 4-8 show the synthetic schemes for the preparation of polyethylene glycol-containing taxanes of the present invention. [20] Figures 9, 10 and 11 show the in vitro cytotoxicity of polyethylene glycol- containing taxanes according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[21] This invention is based on the synthesis of novel taxanes that retain high cytotoxicity and that can be linked effectively to cell binding agents. It has previously been shown that the linkage of highly cytotoxic drugs to antibodies using a cleavable link, such as a disulfide bond, ensures the release of fully active drug inside the cell, and such conjugates are cytotoxic in an antigen specific manner (RN.J. Chari et al, 52 Cancer Res. 127-131 (1992); USP 5,475,092; and USP 5,416,064, 6,340,701 and 6,372,738). However, the art reveals that it is extremely difficult to modify drugs to improve their aqueous solubility without eliminating their cytotoxic potential. The disclosed invention overcomes this problem by modifying the disclosed taxanes with chemical moieties, and especially ones containing polyethylene glycol groups, to which appropriate cell binding agents can be linked. As a result, the disclosed novel taxanes have greater water solubility along with higher cytotoxic potency than that of known taxanes. The cell binding agent-taxane conjugates permit the full measure of the cytotoxic action of the taxanes to be applied in a targeted fashion against unwanted cells only, therefore, avoiding side effects due to damage to non-targeted healthy cells. This invention facilitates the linkage of taxanes to cell binding agents in aqueous media which had previously been difficult. Thus, the invention provides useful agents for the elimination of diseased or abnormal cells that are to be killed, lysed, or destroyed, such as tumor cells (particularly solid tumor cells), virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells (cells that produce autoantibodies), activated cells (those involved in graft rejection or graft vs. host disease), or any other type of diseased or abnormal cells, while exhibiting a minimum of side effects. [22] The cytotoxic agent according to the present invention comprises one or more polyethylene glycol-containing taxanes linked to a cell binding agent via a linking group. The linking group is part of a chemical moiety that is covalently bound to a taxane through conventional methods. In a preferred embodiment, the chemical moiety can be covalently bound to the taxane via a disulfide linkage.
[23] The taxanes useful in the present invention may have the formula (I) shown below:
Figure imgf000009_0001
(I) [24] The novel taxanes of the invention can be divided into two embodiments, (1) and (2) based on the position of the PEG substituent bearing a linking group.
Examples of the two embodiments are shown in Figure 2. [25] In both embodiments, Ri can be H, an electron withdrawing group, such as F,
NO2, CN, CI, CHF2, or CF3 or an electron donating group such as -OCH3, -OCH2CH3,
-NR6R7, -OR8, and Ri' and Ri" are the same or different and can be H, an electron withdrawing group, or an electron donating group. [26] R and R7 are the same or different and each can be H, linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms, or simple or substituted aryl having
1 to 10 carbon atoms. R8 can be linear, branched or cyclic alkyl having 1 to 10 carbon atoms. [27] Preferably, Rβ and R7 are each H or are alkyl or aryl groups having 1 to 4 carbon atoms. Examples of preferred -NR6R groups include dimethyl amino, diethyl amino, dipropyl amino, and dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl. Ri is preferably OMe, OEt, CI, F, NO2, or CF3.
[28] Preferably, Ri is in the meta position and Ri' is OMe, and R|" is H.
[29] In both embodiments, R3 can be aryl or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms, preferably -CH2CH(CH3)2, -CH=C(CH3)2 or -C6H5.
[30] In both embodiments, R can be -OC(CH3)3 or -C6H5.
[31] In embodiment (1) R2 is a PEG-containing linking group and R5 can be H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula -CNR]0Rπ, wherein R10 and Rπ are the same or different and can be H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl. For esters, preferred examples include -COCH3 -COCH2CH5 and -COCH2CH2CH3. For carbamates, preferred examples include -CONHCH2CH3>-CONHCH2CH2CH3, -CO-morpholino, -CO-piperazino, -CO- piperidino, or -CO-N-methylpiperazino.
[32] In embodiment (2), R5 is a PEG-containing linking group and R2 can be H or can have the same definition as above for R5 for embodiment (1)
[33] Suitable linking groups are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups. Preferred are disulfide groups and thioether groups.
[34] When the linking group is a thiol- or disulfide-containing group, the side chain carrying the thiol or disulfide group can be linear or branched, aromatic or heterocyclic. The taxane is linked to the polyethylene glycol through the hydroxyl group on the taxane. The hydroxyl group is used to form, for example, an ether, ester, or carbamate to link to one end of the polyethylene glycol. The moiety that contains the thiol- or disulfide group is linked to the other end of the polyethylene glycol. This linking moiety will contain, for example, an ether, ester, amide or carbamate. One of ordinary skill in the art can readily identify suitable side chains. Specific examples of the thiol- or disulfide- containing side chains include:
Figure imgf000011_0001
Ri3 M)ι(OCH2CΗ2)1,0(C R,3Ri4)ι(CH2)r„(CR,3Ri4)ιSZ, -CO(C R13R14),(CH2)m(C R13R14). (OCH2CH2)nO(C R13RI4),(CH2)m(C R13RI4), SZ, -CONR12(C R13R14),(CH2)m(C R13R14)-(OCH2CH2)nO(C R13R14)ι(CH2)m(CR13R14), SZ, -(CR,3R14)1(CH2)m(CR13R14)1(OCH2CH2)„OCO(CR13R14)1(CH2)m(CR13R14),SZ, -(CR13R14)1(CH2)m(CR13R14),(OCH2CH2)nNR12CO(CR13R14)i(CH2)m(CR13R14),SZ, -(CRI3Rι4)1(CH2)m(CR13R14)1(OCH2CH2)nOCONRI2(CR13R,4),(CH2)m(CRι3R14)ιSZ, -CO(CR13RI4)1(CH2)m(CR13R14), (OCH2CH2)nOCO(CR13R14)1(CH2)m(CRι3R14), SZ, -CO(CR13R14)1(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14),(CH2)m(CR13Ri4)ι SZ, -CO(CR13R14),(CH2)m(CR13R14)1(OCH2CH2)nOCONR12(CR13R14)1(CH2)m(CR13Rι4)1 SZ, -CONR12(CR13R14)1(CH2)m(CR,3Rι4),(OCH2CH2)nOCO(CRI3R14),(CH2)m(CR13R14), SZ, -CONR12(CR13R14)I(CH2)m(CR13Ri4)ι(OCH2CH2)nNR12CO(CR13Rι4)1(CH2)m(CR13Rι4),
SZ, -CONR12(CR,3R14),(CH2)m(CR13R,4)ι(OCH2CH2)nOCONR,2(CR13R14)1(CH2)m- (CRι3Rι4)ι SZ, -CO-mo hol_no-X(OCH2CH2)nSZ, -CO-piρerazino-X(OCH2CH2)nSZ, -CO-piperidino-X(OCH2CH2)nSZ, and -CO-N-methylρiρerazino-X(OCH2CH2)nSZ, wherein [35] Z is H or SR,
[36] X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
[37] R and R12 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl or heterocyclic, and R12 can in addition be H, [38] Rι3 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl, [39] 1 is 0 or an integer from 1 to 10,
[40] m is an integer of 1 to 10, and
[41] n is 2 to 1000.
[42] Examples of linear alkyls include methyl, ethyl, propyl, butyl, pentyl and hexyl. [43] Examples of branched alkyls include isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and 1-ethyl-propyl. [44] Examples of cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. [45] Examples of simple aryls include phenyl and naphthyl.
[46] Examples of substituted aryls include aryls such as those described above substituted with alkyl groups, with halogens, such as CI, Br, F, nitro groups, amino groups, sulfonic acid groups, carboxylic acid groups, hydroxy groups or alkoxy groups. [47] Examples of heterocyclics are compounds wherein the heteroatoms are selected from O, N, and S, and include morpholino, piperidino, piperazino, N- methylpiperazino, pyrrollyl, pyridyl, furyl and thiophene. [48] The taxanes of the present invention that have a PEG-containing thiol- or disulfide-containing substituent are in themselves novel. [49] The taxanes that have a PEG-containing thiol or disulfide-containing substituent can be synthesized according to known methods. The starting material for the synthesis is the commercially available 10-deacetylbaccatin III, shown in Figure 3. The chemistry to introduce various substituents is described in several publications (Ojima et al, J.Med. Chem.39, 3889-3896, (1996), Ojima et al., 40 J. Med. Chem. 267-278 (1997); I. Ojima et al., 96 Proc. Natl. Acad. Set, 4256-4261 (1999); I. Ojima et al., USP 5,475,011 and USP 5,811,452).
[50] The substituent Ri on the phenyl ring and the position of the substituent Ri can be varied until a compound of the desired toxicity is obtained. Furthermore, the degree of substitution on the phenyl ring can be varied to achieve a desired toxicity. That is, the phenyl ring can have one or more substituents (e.g., mono-, di-, or tri- substitution of the phenyl ring) which provide another means for achieving a desired toxicity. High cytotoxicity is defined as exhibiting a toxicity having an IC50 in the range of 1 x 10"12 to 3 x 10"9 M, when measured in vitro with cultured cancer cells upon a 72 hour exposure time to the drug. One of ordinary skill in the art can determine the appropriate chemical moiety for Rj and the appropriate position for Ri using only routine experimentation.
[51] For example electron donating groups at the meta position are expected to increase the cytotoxic potency, while substitution at the para position is not expected to increase the potency as compared to the parent taxane. Typically a few representative taxanes with substituents at the different positions (ortho, meta and para) will be initially prepared and evaluated for in vitro cytotoxicity.
[52] The disulfide or thiol-containing substituent can be incorporated into the PEG group that is introduced by reaction at the one of the hydroxyl substituents in the taxane skeleton. The chemistry to protect the various hydroxyl groups, while reacting the desired one, has been described previously (see, for example, the references cited supra). The substituent is introduced by simply converting the free hydroxyl group to a PEG-containing ether, a PEG-containing ester, or a PEG-containing carbamate. This transformation is achieved as follows. The desired hydroxyl group is deprotonated by treatment with the commercially available reagent lithium hexamethyldisilazane (1.2 equivalents) in tetrahydrofuran at -40°C as described in I. Ojima et al, supra. The resulting alkoxide anion is then reacted with halogenated PEG bearing an appropriately protected thiol substituent, followed by deprotection of the thiol group to provide the desired thiol-containing PEGylated taxane. The thiol group can be converted into a methyl or pyridyl disulfide by reaction with methyl methane thiolsulfonate or dithiodipyridine respectively. This method is described in USP 5,416,064.
[53] Altematively, the desired hydroxyl group can be esterified directly by reaction with a carboxy-PEG bearing a disulfide-containing substituent, in the presence of a coupling agent such as di-isopropylcarbodiimide (DIC), to provide a disulfide-containing PEGylated taxane ester. Reduction of the disulfide substituent can then provide the thiol-containing PEGylated taxane ester. In order to prepare disulfide-containing carbamates, the hydroxyl group can be reacted with a commercially available chloroformate, such as para-nitrophenyl chloroformate, followed by reaction with an amino-PEG bearing a disulfide-containing substituent. Representative synthetic schemes are shown in Figures 4 to 8 and the methods are described in Example 2.
[54] Disulfide-containing and thiol-containing PEGylated taxane drugs of the invention can be evaluated for their ability to suppress proliferation of various unwanted cell lines in vitro. For example, cell lines such as the human lung carcinoma line A549, the human breast tumor line MCF-7, and the Burkitt's lymphoma line Namalwa can easily be used for the assessment of cytotoxicity of these compounds. Cells to be evaluated can be exposed to the compounds for 72 hours and the surviving fractions of cells measured in direct assays by known methods. IC50 values can then be calculated from the results of the assays. Results from the testing of PEGylated taxoids of this invention are shown in Figures 9, 10, and 11. PEGylated taxoid 17 is extremely potent with an IC50 value of 6.3 x 10"1 ' M towards MCF-7 cells. PEGylated taxoid 17 is shown to have the same high in vitro potency as the coπesponding non-PEGylated parent taxoid 1 towards A-431 cells (IC5Q for both taxoids = 3.3 x 10"10 M). Pegylated taxoid 20 is also highly potent, with an IC50 value of 3.2 x 10'10 M towards MCF-7 cells.
[55] The effectiveness of the compounds of the invention as therapeutic agents depends on the selection of an appropriate cell binding agent. Cell binding agents may be of any kind presently known, or that become known and include peptides and non-peptides. The cell-binding agent may be any compound that can bind a cell, either in a specific or nonspecific manner. Generally, these can be antibodies, or fragments thereof (especially monoclonal antibodies), lymphokines, hormones, growth factors, vitamins, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance.
[56] More specific examples of cell binding agents that can be used include:
- resurfaced antibodies (U.S. Pat. No. 5,639,641), humanized or fully human antibodies;
- single chain antibodies (Oi, V.T. & Morrison, S. 4 BioTechniques, 214-221
(1986), Raag, R & Whitlow, M. 9 FASEB J. 73-80 (1995), Reiter, Y. et al. 14 Nature
Biotechn. 1239-12145 (1996)); - chimeric antibodies (U.S. Pat. No. 4,816,567):
- fragments of antibodies such as sFv, Fab, Fab', and F(ab')2 (Parham, 131 J. Immunol. 2895-2902 (1983); Spring et al, 113 J. Immunol. 470-478 (1974));
Nisonoff et al, 89 _4rcΛ. Biochem. Biophys. 230-244 (I960));
-interferons (e.g. α, β, γ);
-lymphokines such as IL-2, IL-3, IL-4, IL-6;
-hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens;
-vitamins such as folic acid;
-growth factors and colony-stimulating factors such as EGF, TGF-α, VEGF,
PDGF, FGF, IGF-1, IGF-2, Somatostatin, G-CSF, M-CSF and GM-CSF (Burgess, 5 Immunology Today 155-158 (1984)); and
-transferrin (O'Keefe et al, 260 J. Biol. Chem. 932-937 (1985)).
[57] Monoclonal antibody techniques allow for the production of extremely specific cell binding agents in the form of specific monoclonal antibodies or fragments thereof. Particularly well known in the art are techniques for creating monoclonal antibodies, or fragments thereof, by immunizing mice, rats, hamsters, or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins. Sensitized human cells can also be used. Another method of creating monoclonal antibodies, or fragments thereof, is the use of phage libraries of sFv (single chain variable region), specifically human sFv. (See e.g., Griffiths et al., USP 5,885,793; McCafferty et al., WO 92/01047; Liming et al., WO 99/06587).
[58] Selection of the appropriate cell binding agent is a matter of choice that depends upon the particular cell population to be targeted, but in general, monoclonal antibodies are preferred if an appropriate one is available.
[59] For example, the monoclonal antibody MY9 is a murine IgGi antibody that binds specifically to the CD33 Antigen (J.D. Griffin et al 8 Leukemia Res., 521 (1984)) and can be used if the target cells express CD33 such as in the disease of acute myelogenous leukemia (AML). Similarly, the monoclonal antibody anti-B4 is a murine IgGi, that binds to the CD 19 antigen on B cells (Nadler et al, 131 J. Immunol. 244-250 (1983)) and can be used if the target cells are B cells or diseased cells that express this antigen, such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia. Similarly, the antibody N901 is a murine monoclonal IgGi antibody that binds to CD56 found on small cell lung carcinoma cells and on cells of other tumors of neuroendocrine origin (Roy et al. J. Nat. Cancerlnst. 88:1136-1145 (1996)).
[60] Additionally, GM-CSF, which binds to myeloid cells, can be used as a cell binding agent to diseased cells from acute myelogenous leukemia. IL-2 which binds to activated T-cells can be used for prevention of transplant graft rejection, for therapy and prevention of graft- versus-host disease, and for treatment of acute T-cell leukemia. MSH, which binds to melanocytes, can be used for the treatment of melanoma. Folic acid, which targets the folate receptor expressed on ovarian and other cancers, is also a suitable cell binding agent. [61] Cancers of the breast and testes can be successfully targeted with estrogen (or estrogen analogues) or androgen (or androgen analogues), respectively, as cell binding agents.
[62] Conjugates of the PEGylated taxanes of the invention and a cell binding agent can be formed using any techniques presently known or later developed. Numerous methods of conjugation are taught in USP 5,416,064 and USP 5,475,092. The PEGylated taxane ester can be modified to yield a free amino group and then linked to an antibody or other cell binding agent via an acid labile linker or a photolabile linker. The PEGylated taxane ester can be condensed with a peptide and subsequently linked to a cell binding agent to produce a peptidase labile linker. The hydroxyl group on the PEGylated taxane ester can be succinylated and linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free drug. Most preferably, the PEGylated taxane ethers, esters, or carbamates are treated to create a free or protected thiol group, and then the disulfide- or thiol-containing taxanes are linked to the cell binding agent via disulfide bonds.
[63] Representative conjugates of the invention are antibody-PEGylated-taxane, antibody fragment-PEGylated-taxane, epidermal growth factor (EGF)-PEGylated-
taxane, (TGF-α)-PEGylated-taxane, (FGF)-PEGylated-taxane, (PDGF)-PEGylated-
taxane, melanocyte stimulating hormone (MSH)-PEGylated-taxane, (IGF-1)- PEGylated-taxane, (IGF-2)-PEGylated-taxane, (Somatostatin)-PEGylated-taxane, thyroid stimulating hormone (TSH)-PEGylated-taxane, estrogen-PEGylated-taxane, estrogen analogue-PEGylated-taxane, androgen-PEGylated-taxane, androgen analogue-PEGylated-taxane, and folate-PEGylated-taxane. [64] PEGylated-taxane conjugates of antibodies, antibody fragments, protein or peptide hormones, protein or peptide growth factors and other proteins are made in the same way by known methods. For example, peptides and antibodies can be modified with cross linking reagents such as N-succinimidyl 3-(2- pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate
(SPP), 4-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyl dithio)-toluene (SMPT),
Ν-succinimidyl-3-(2-pyridyldithio) butyrate (SDPB), 2-iminothiolane, or S-acetylsuccinic anhydride by known methods. See, Carlsson et al, 173 Biochem. J. 723-737 (1978); Blattler et al, 24 Biochem. 1517-1524 (1985); Lambert et al, 22 Biochem. 3913-3920 (1983); Klotz et al, 96 Arch. Biochem. Biophys. 605 (1962); and Liu et al, 18 Biochem. 690 (1979), Blakey and Thorpe, 1 Antibody, Immunoconjugates and Radiopharmaceuticals, 1-16 (1988), Worrell et al 1 Anti-Cancer Drug Design 179-184 (1986). The free or protected thiol-containing cell binding agent thus derived is then reacted with a disulfide- or thiol-containing taxane to produce conjugates. The conjugates can be purified by HPLC or by gel filtration.
[65] Similarly, for example, estrogen and androgen cell binding agents such as estradiol and androstenediol can be esterified at the C-17 hydroxy group with an appropriate disulfide containing carboxylic acid using e.g., dicyclohexylcarbodiimide as a condensing agent. Examples of such carboxylic acids that can be employed are 3-(2-pyridyldithio) propanoic acid, 3-methyldithiopropanoic acid, 4-(2-pyridyldithio) pentanoic acid, and 3-phenyldithiopropanoic acid. Esterification of the C-17 hydroxy group can also be achieved by reaction with an appropriately protected thiol group containing carboxylic acid chloride such as 3-S-acetylpropanoyl chloride. Other methods of esterification can also be employed as described in the literature (Haslam, 36 Tetrahedron 2409-2433 (1980)). The protected or free thiol containing androgen or estrogen can then be reacted with a disulfide- or thiol-containing PEGylated taxane to produce conjugates. The conjugates can be purified by column chromatography on silica gel or by HPLC. Folic acid can be condensed with a suitable hydrazide such as 4-(2-pyridyldithio) pentanoic acid hydrazide in the presence of a condensing agent such as dicyclohexyl carbodiimide to give a hydrazone containing an active disulfide. The disulfide-containing folate can then be reacted with a thiol-containing taxane to produce a conjugate that can be purified by column chromatography over silica gel or by HPLC
[66] Preferably monoclonal antibody- or cell binding agent-PEGylated-taxane conjugates are those that are joined via a disulfide bond, as discussed above, that are capable of delivering the PEGylated taxane molecules. Such cell binding conjugates are prepared by known methods such as by modifying monoclonal antibodies with succinimidyl pyridyl-dithiopropionate (SPDP) (Carlsson et al, 173 Biochem. J. 723- 737 (1978)). The resulting thiopyridyl group is then displaced by treatment with thiol-containing PEGylated taxanes to produce disulfide linked conjugates. Alternatively, in the case of the aryldithio-taxanes, the formation of the cell binding conjugate is effected by direct displacement of the aryl-thiol of the PEGylated taxane by sulfhydryl groups previously introduced into antibody molecules. Conjugates containing 1 to 10 taxane drugs linked via a disulfide bridge are readily prepared by either method.
[67] More specifically, a solution of the dithiopyridyl modified antibody at a concentration of 1 mg/ml in 0.1 M potassium phosphate buffer, at pH 6.5 containing 1 mM EDTA is treated with the thiol-containing PEGylated taxane (1.7 molar eq./ dithiopyridyl group). The release of thiopyridine from the modified antibody is monitored spectrophotometrically at 343 nm and is complete in about 20 hours. The antibody-taxane conjugate is purified and freed of unreacted drug and other low molecular weight material by gel filtration through a column of Sephadex G-25 or Sephacryl S300. The number of taxane moieties bound per antibody molecule can be determined by measuring the ratio of the absorbance at 230 nm and 275 nm. An average of 1-10 taxane molecules/antibody molecule can be linked via disulfide bonds by this method.
[68] Antibody-PEGylated taxane conjugates with non-cleavable links can also be prepared. The antibody can be modified with crosslinking reagents such as succinimidyl 4-(maleimidomethyl)cyclohexane-l-carboxylate (SMCC), sulfo-SMCC, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), sulfo-MBS or succinimidyl-iodoacetate, as described in the literature, to introduce 1-10 reactive groups. See, Yoshitake et al, 101 Eur. J. Biochem. 395-399 (1979); Hashida et al, J. Applied Biochem. 56-63 (1984); and Liu et al, 18 Biochem. 690-697 (1979). The modified antibody is then reacted with the thiol-containing taxane derivative to produce a conjugate. The conjugate can be purified by dialysis, or by gel filtration through a Sephadex G-25 or Sephacryl S-300 column.
[69] The modified antibodies, or fragments thereof, are treated with the thiol-containing PEGylated taxanes (1.25 molar equivalent/maleimido group). The mixtures are incubated overnight at ambient temperature. The antibody-taxane conjugates are purified by dialysis, or by gel filtration through a Sephadex G-25 or Sephacryl S-300 column. Typically, an average of 1 to 10 taxanes per antibody are linked. [70] A prefeπed method is to modify antibodies, or fragments thereof, with succinimidyl-4-(maleimidomethyl)-cyclohexane-l-carboxylate (SMCC) to introduce maleimido groups followed by reaction of the modified antibody or fragment with the thiol-containing PEGylated taxanes to give a thioether linked conjugate. Again, conjugates with 1 to 10 drug molecules per antibody molecule result.
[71] Cytotoxicity of the PEGylated taxanes and their antibody conjugates to non- adherent cell lines such as Namalwa and HL-60 can be measured by back- extrapolation of cell proliferation curves as described in Goldmacher et al, 135 J. Immunol. 3648-3651 (1985). Cytotoxicity of these compounds to adherent cell lines such as SKBR3 and A431 can be determined by clonogenic assays as described in Goldmacher et al, 102 J. Cell Biol. 1312-1319 (1986).
[72] The present invention also provides a therapeutic composition comprising:
[73] (A) an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and
[74] (B) a pharmaceutically acceptable carrier, diluent, or excipient.
[75] Similarly, the present invention provides a method of killing selected cell populations comprising contacting the target cells or tissue containing target cells with a cytotoxic amount of the above-described cytotoxic agent.
[76] The cytotoxic agent is prepared as described above.
[77] Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of ordinary skill in the art as the clinical situation warrants. [78] Examples of suitable carriers, diluents and/or excipients include: (1 )
Dulbecco's phosphate buffered saline, pH about 7.4, containing or not containing about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose; and may also contain an antioxidant such as tryptamine and a stabilizing agent such as Tween 20.
[79] The method for killing selected cell populations can be practiced in vitro, in vivo, or ex vivo.
[80] Examples of in vitro uses include treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells; treatments of bone maπow prior to their transplantation in order to kill competent T cells and prevent graft- versus-host-disease (GVHD); treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen or to kill variants that express undesired antigen.
[81] The conditions of non-clinical in vitro use are readily determined by one of ordinary skill in the art.
[82] Examples of clinical ex vivo use are to remove tumor cells or lymphoid cells from bone marrow prior to autologous transplantation in cancer treatment or in treatment of autoimmune disease, or to remove T cells and other lymphoid cells from autologous or allogenic bone marrow or tissue prior to transplant in order to prevent GVHD. Treatment can be carried out as follows. Bone marrow is harvested from the patient or other individual and then incubated in medium containing serum to which is
added the cytotoxic agent of the invention, concentrations range from about 10 μM to 1 pM, for about 30 minutes to about 48 hours at about 37°C. The exact conditions of concentration and time of incubation, i.e., the dose, are readily determined by one of ordinary skill in the art. After incubation the bone marrow cells are washed with medium containing serum and returned to the patient intravenously according to known methods. In circumstances where the patient receives other treatment such as a course of ablative chemotherapy or total-body irradiation between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
[83] For clinical in vivo use, the cytotoxic agent of the invention will be supplied as a solution or a lyophihzed powder that are tested for sterility and for endotoxin levels. Examples of suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 4 weeks as an intravenous bolus each week. Bolus doses are given in 50 to 100 ml of normal saline to which 5 to 10 ml of human serum
albumin can be added. Dosages will be 10 μg to 2000 mg per administration,
intravenously (range of 100 ng to 20mg/kg per day). After four weeks of treatment, the patient can continue to receive treatment on a weekly basis. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by one of ordinary skill in the art as the clinical situation warrants.
[84] Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any type including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, and lymphatic organs; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc.; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and others as determined by one of ordinary skill in the art.
EXAMPLES
[85] The invention will now be illustrated by reference to non-limiting examples.
Unless otherwise stated, all percents, ratios, parts, etc. are by weight.
EXAMPLE 1 IN VITRO CYTOTOXICITY ASSAYS [86] The sulfide, disulfide, and sulfhydryl containing PEGylated taxane drugs of the invention can be evaluated for their ability to suppress proliferation of various human tumor cell lines in vitro. Two adherent cell lines A549(human lung carcinoma) and MCF-7 (human breast tumor) and the non-adherent cell line,
Namalwa (Burkitt's lymphoma) are used for the assessment of cytotoxicity of these compounds. Cells are exposed to the compounds for 72 hours and the surviving fractions of cells are measured in direct assays. (A549 and MCF-7 are assayed for plating efficiency (Goldmacher et al, 102 J. Cell. Biol. 1312-1319 (1986) and
Namalwa are assayed by growth back extrapolation (Goldmacher et al, 135 J.
Immunol. 3648-3651 (1985)). IC50 values are then calculated from this data.
EXAMPLE 2 SYNTHESIS OF PEGYLATED TAXANES Materials and Methods
[87] Melting points were measured using an Electrothermal apparatus and are uncorrected. NMR spectra were recorded on a Bruker AVANCE400 (400 MHz) spectrometer. Chemical shifts are reported in ppm relative to TMS as an internal standard. Mass spectra were obtained using a Bruker Esquire 3000 system. Ultraviolet spectra were recorded on a Hitachi U1200 spectrophotometer. HPLC was performed using a Beckman Coulter GOLD 125 system equipped with a Beckman Coulter system GOLD 168 variable wavelength detector and a VYDAC reverse phase C-18 column. Thin layer chromatography was performed on Analtech GF silica gel TLC plates. Silica gel for flash column chromatography was from Baker. Tetrahydrofuran was dried by distillation over sodium metal. Dimethylactamide and dimethylformamide were dried by distillation over calcium hydride under reduced pressure. All other solvents used were reagent grade or HPLC grade. [88] 7,10,13-Tri(triethylsilyl)-10-deacetylbaccatin III (2)- To a solution of 10-
DAB (1) (2.64 g, 4.85 mmol) and imidazole (1.65 g, 24.3 mmol) in dry NN- dimethylformamide (DMF, 8 mL) was added chlorotriethylsilane (4.89 mL, 29.1 mmol) dropwise via syringe at room temperature. The reaction mixture was stiπed for 48 h at room temperature and diluted with ethyl acetate (300 mL). The mixture was then washed with ammonium chloride (100 mL x 3), water (100 ml), brine (100 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude product was purified on a silica gel column using 20% ethyl acetate in hexane as the
eluant to give 2 as a white solid (4.08 g, 95%): mp 187-189 °C; H ΝMR (CDCI3) δ
0.65 (m, 18 H), 0.99 (m, 27 H), 1.11 (s, 3 H), 1.18 (s, 3 H), 1.64 s, 3 H), 1.87 (m, 1 H), 1.97 (s, 3 H), 2.08 (dd, J= 15.2, 8.8 Hz, 1 H), 2.21 (dd, J= 15.1, 8.2 Hz, 1 H), 2.27 (s, 3 H), 2.51 (m, 1 H), 3.84 (d, J= 7.0 Hz, 1 H), 4.13 (d, J= 8.3 Hz, 1 H), 4.27 (d, J= 8.3 Hz, 1 H), 4.40 (dd, J= 10.5, 6.6 Hz, 1 H), 4.92 (m, 2 H), 5.18 (s, 1 H), 5.61 (d, J= 7.1 Hz, 1 H), 7.44 (t, J= 7.3 Hz, 2 H), 7.57 (t, J= 7.3 Hz, 1 H), 8.07 (d, J= 7.4 Hz, 1 H); 13C NMR (CDCI3) δ 4.7, 5.2, 5.9, 6.9, 10.4, 14.8, 20.5, 22.4, 26.3, 37.3,
19.8, 42.4, 46.8, 58.2, 68.3, 72.6, 75.4, 75.7, 76.6, 79.5, 80.7, 83.9, 128.5, 129.6, 130.0, 133.4, 135.7, 139.3, 167.1, 169.7, 205.6. m/z LC/MS for C47H78OιoSi3Na+: calcd: 909.48; found: 909.28. [89] 7,10,13-Tri(triethyIsilyI)-2-debenzoyI-10-deacetylbaccatin III (3)- To a solution of 2 (1.43 g, 1.59 mmol) in dry THF (80 mL) at -10 °C was added dropwise a solution of Red-Al in toluene (1.9 mL, 65% wt), and the reaction mixture was strrred for 60 min at -10 °C. The reaction was quenched with aqueous saturated ammonium chloride solution (150 mL), and the aqueous layer was extracted with ethyl acetate (75 ml x 3). The combined extracts were then dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified on a silica gel column using 25% ethyl acetate in hexane as the eluant to afford 3 as a white solid (1.21 g, 97%.):
mp 68-70 °C; lK NMR (CDCI3) δ 0.57 (m, 18 H), 0.94 (m, 27 H), 1.11 (s, 3 H), 1.55
(s, 3 H), 1.87 (m, 1 H), 1.88 (s, 3 H), 1.94 (m, 1 H), 2.00 (m, 1 H), 2.12 (s, 3 H), 2.47 (m, 1 H), 3.42 (d, J= 6.6 Hz, 1 H), 3.80 (d, J= 6.6 Hz, 1 H), 4.31 (dd, J= 10.4, 6.5 Hz, 1 H), 4.50 (d, J= 9.0 Hz, 1 H), 4.57 (d, J= 9.1 Hz, 1 H), 4.63 (s, 1 H), 4.89 (d, J
= 8.3 Hz, 1 H), 4.91 (m, 1 H), 5.08 (s, 1 H); 13C NMR (CDCI3) δ 4.7, 5.1, 5.8, 6.7,
6.8, 10.5, 14.4, 20.5, 22.3, 37.3, 40.3, 42.5, 58.1, 65.0, 66.3, 72.6, 74.6, 75.7, 77.9, 78.5, 81.9, 83.7, 126.8, 127.4, 128.4, 135.9, 138.9, 169.6, 206.3. m/z LC/MS for C40H7 O9Si3Na+: calcd: 805.45; found: 805.33. [90] 7,10,13-Tri(triethylsilyl)-2-debenzoyI-2-(2,5-dimethoxybenzoyl)-10- deacetylbaccatin III (4)- A solution of 3 (366 mg, 0.468 mmol), 2,5-Dimethoxy benzoic acid (892 mg, 4.9 mmol), DCC (1.0 g, 4.9 mmol), and 4-pyrrolidinopyridine (10 mg, 0.07 mmol) in toluene (4 mL) was stirred for 24 h at 60 degrees. The reaction was monitored by tic using 40% ethyl acetate in hexane. After cooling to room temperature, the reaction was diluted with 10 mL of 20% ethyl acetate in hexane and passed through a short pad of silica gel using 200 mL of the same solution to wash the silica, and the resulting filtrate was concentrated. The crude residue obtained was purified on a silica gel column using 40% ethyl acetate in hexane as the eluant to give 4 as a white solid, which contained small amounts of DCC and acid. The product was used without further purification. A small sample was purified the
same way to yield a pure analytical sample. lH NMR (CDCI3) δ lH NMR (CDCI3)
δ 0.60 (m, 18 H), 0.90 (m, 27 H), 1.13 (s, 3 H), 1.16 (s, 3 H), 1.64 (s, 3 H), 1.88 (m, 1
H), 1.94 (s, 3 H), 2.13 (s, 3 H), 2.22 (m, 2 H), 2.35 (s, 3 H), 2.43 (m, 2 H), 3.76 (s, 3 H), 3.78 (d, J= 7.1 Hz, 1 H), 3.85 (s, 3 H), 4.24 (d, J= 2.0 Hz, 1 H), 4.27 (m, 2 H), 4.35 (dd, J= 6.4, 10.4 Hz, 1 H), 4.88 (d, J= 8.0 Hz, 1 H), 4.96 (t, J= 8.0 Hz, 1 H), 5.15 (s, 1 H), 5.60 (d, J= 6.4 Hz, 1 H), 6.91 (d, J= 8.9 Hz, 1 H), 7.02 (dd, J= 8.9, 3.4 Hz, 1 H), 7.38 (d, J= 3.4 Hz 1 H). m/z LC/MS for C49H82Oι2Si3Na+: calcd: 969.50; found: 969.39. [91] 2-Debenzoyl-2-(2,5-dimethoxybenzoyl)-10-deacetylbaccatin III (5)- To the crude solution of 4 (-400 mg) in pyridine-acetonitrile (1/1, 30 mL) was added dropwise HF/pyridine (70:30, 5 mL) at 0 °C, and the mixture was stirred for 24 h with warming to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate. The reaction mixture was then diluted with ethyl acetate (60 mL), washed with saturated aqueous copper sulfate (20 mL x 2) and water (20 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo to afford 2- debenzoyl-2-(2,5-Dimethoxybenzoyl)-10-deacetylbaccatin III, 5 as a white solid (198 mg, 62% yield for 2 steps. lK NMR (CDCI3) δ 1.09 (s, 3 H), 1.12 (s, 3 H), 1.77 (s, 3
H), 1.83 (m, 1 H), 2.06 (m, 4 H), 2.15 (s, 3 H), 2.27 (m, 2 H), 2.58 (m, 2 H), 3.81 (s, 3 H), 3.89 (s, 3 H), 3.93 (d, J= 6.8 Hz, 1 H), 4.18 (d, J= 2.0 Hz, 1 H), 4.24 (m, 1 H), 4.33 (m, 2 H), 4.92 (m, 2 H), 5.30 (s, 1 H), 5.62 (d, J= 6.8 Hz, 1 H), 6.93 (d, J= 8.9 Hz, 1 H), 7.06 (dd, J= 8.9, 3.4 Hz, 1 H), 7.38 (d, J= 3.4 Hz 1 H). m z LC/MS for C3ιH40Oι2Na+: calcd: 627.25; found: 627.31. [92] 7-TriethyIsiIy_-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-10-deacetylbaccatin
III (6)- To a solution of 5 thus obtained (86 mg, 0.139 mmol) and imidazole (40 mg,
0.556 mmol) in dry DMF (4 mL) was added chlorotriethylsilane (70 μL, 0.420 mmol)
via syringe at 0 °C. The ice bath was removed and the reaction mixture was stirred for 3 h at rt and diluted with ethyl acetate (50 mL). The mixture was then washed with aqueous ammonium chloride (25 mL x 2), brine (25 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude product was purified on a silica gel column using 60 % ethyl acetate in hexane as the eluant to give 6 as a white
solid (87 mg, 88%): H NMR (CDCI3) δ 0.54 (m, 6 H), 0.90 (t, J = 8.0 Hz, 9 H),
1.02 (s, 3 H), 1.08 (s, 3 H), 1.72 (s, 3 H), 1.86 (m, 1 H), 2.10 (m, 4 H), 2.13 (s, 3 H), 2.22 (m, 2 H), 2.43 (m, 1 H), 2.58 (s, 1 H), 2.72 (m, 1 H), 3.78 (s, 3 H), 3.86 (d, J= 7.1 Hz, 1 H), 3.87 (s, 3 H), 4.25 (d, J= 2.0 Hz, 1 H), 4.29 (m, 2 H), 4.35 (dd, J= 6.4, 10.4 Hz, 1 H), 4.84 (br t, 1 H), 4.91 (d, J= 8.6 Hz, 1 H), 5.13 (d, J= 2.0 Hz, 1 H), 5.56 (d, J= 6.8 Hz, 1 H), 6.91 (d, J= 8.9 Hz, 1 H), 7.04 (dd, J= 8.9, 3.4 Hz, 1 H), 7.37 (d, J= 3.4 Hz 1 H). m/z LC/MS for C37H5 Oι2SiNa+: calcd: 741.34; found: 741.39. [93] 7-TriethyIsilyl-2-debenzoyI-2-(2,5-dimethoxybenzoyl)baccatin III (7)-
To a solution of 6 (87 mg, 0.121 mmol) in dry THF (7 mL) was added 1.0 M
LiHMDS in THF (170 μL, 0.170 mmol) dropwise via syringe at -40 °C. The mixture
was stirred at -40 °C for 5 min, and freshly distilled acetyl chloride (12 μL, 0.170
mmol) was added. After 2 hr at -40 °C, the reaction was quenched with saturated aqueous ammonium chloride (5 mL), extracted with dichloromethane (10 mL x 3). The combined extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude product was purified on a silica gel column using 60% ethyl acetate in hexane as the eluant to afford 7 as a white solid (70 mg, 77%
yield): lH NMR (CDCI3) δ 0.55 (m, 6 H), 0.91 (t, J = 8.0 Hz, 9 H), 1.06 (s, 3 H),
1.18 (s, 3 H), 1.70 (s, 3 H), 1.72 (m, 1 H), 1.86 (m, 1 H), 2.15 (s, 3 H), 2.17 (s, 3 H), 2.22 (m, 3H), 2.49 (m, 1 H), 2.61 (s, 1 H), 3.80 (s, 3 H), 3.81 (d, J= 7.1 Hz, 1 H), 3.88 (s, 3 H), 4.28 (d, J= 8.4 Hz, 1 H), 4.31 (d, J= 8.4 Hz, 1 H), 4.44 (dd, J= 6.4, 10.4 Hz, 1 H), 4.84 (br t, 1 H), 4.91 (d, J= 8.6 Hz, 1 H), 5.61 (d, J= 6.4 Hz, 1 H), 6.43 (s, 1 H), 6.93 (d, J= 9.2 Hz, 1 H), 7.06 (dd, J= 9.2, 3.2 Hz, 1 H), 7.37 (d, J= 3.2 Hz 1 H). m/z LC/MS for C39H56Oι3SiNa+: calcd: 783.35; found: 783.36. [94] 7-(TriethylsilyI)-2'-(triisopropylsilyloxy)-3'-dephenyl-3,-(isobutenyl)-2- debenzoy_-2-(2,5-dimethoxybenzoy_)-10-acetyl-docetaxeI (9)- To a solution of 7
(70 mg, 0.092 mmol) and β-lactam 8 (52 mg, 0.13 mmol) in dry THF (7 mL) was
added a solution of 1.0 M LiHMDS in THF (0.13 mL, 0.13 mmol) dropwise at -40 °C, and the solution was stiπed at -40 °C for 3 hours. The reaction was quenched with saturated aqueous ammonium chloride (10 mL), and the aqueous layer was extracted with ethyl acetate (15 ml x 3). The combined extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified on a silica gel column using 40% ethyl acetate in hexane as the eluant to afford the coupled
product 9 as a white solid (62 mg, 61%): lK NMR (CDCI3) δ 0.55 (m, 6 H), 0.91 (t, J
= 8.0 Hz, 9 H), 1.11 (m, 27 H), 1.20 (s, 3 H), 1.23 (s, 3 H), 1.37 (m, 10 H), 1.69 (s, 3 H), 1.72 (m, 6 H), 1.89 (m, 1 H), 1.98 (s, 3 H), 2.15 (s, 3 H), 2.17 (s, 3 H), 2.17 (s, 3 H), 2.34 (m, IH), 2.49 (m, 2 H), 3.74 (d, J= 6.8 Hz, 1 H), 3.80 (s, 3 H), 3.96 (s, 3 H), 4.27 (d, J= 8.0 Hz, 1 H), 4.41 (m, 3 H), 4.75 (t, J= 8.0 Hz, 1 H), 4.88 (m, 2 H), 5.34 (d, J= 8.4 Hz, 1 H), 5.67 (d, J= 6.8 Hz, 1 H), 6.07 (t, J= 9.0 Hz, 1 H), 6.45 (s, 1 H), 6.93 (d, J= 9.2 Hz, 1 H), 7.05 (dd, J= 9.2, 3.2 Hz, 1 H), 7.29 (d, J= 2.8 Hz 1 H). m z LC/MS for C60H95NOι7Si2Na+: calcd: 1180.61; found: 1180.47.
[95] 7-(TriethyIsilyl)-2'-(triisopropylsπyloxy)-3'-dephenyI-3'-(isobutenyl)-2- debenzoyl-2-(2,5-dimethoxybenzoyl)-docetaxel (10)- To a solution of 9 (36 mg, 0.031 mmol) in ethanol (1.5 mL) was added hydrazine monohydrate (1 mL) at room temperature. The reaction was stirred at rt and monitored by tic using 40% ethyl acetate in hexane (developed twice). After 1 hour the reaction was complete by tic and quenched with saturated aqueous ammonium chloride (10 mL). The aqueous layer was extracted with ethyl acetate (10 ml x 3). The combined extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified on a silica gel column using 35% ethyl acetate in hexane as the eluant to
afford the deacetylated product 10 as a white solid (19 mg, 57%): lU NMR (CDCI3)
δ 0.56 (m, 6 H), 0.92 (t, J = 8.0 Hz, 9 H), 1.11 (m, 27 H), 1.22 (s, 3 H), 1.23 (s, 3 H), 1.38 (m, 10 H), 1.69 (s, 3 H), 1.72 (m, 3 H), 1.78 (s, 3 H), 1.89 (s, 3 H), 1.93 (m, 1 H), 2.18 (s, 3 H), 2.32 (m, IH), 2.44 (m, 2 H), 3.81 (s, 3 H), 3.82 (d, J= 6.8 Hz, 1 H), 3.96 (s, 3 H), 4.25 (d, J= 2.0 Hz, 1 H), 4.29 (d, J= 8.0 Hz, 1 H), 4.34 (dd, J= 6.4, 10.4 Hz, 1 H), 4.39 (d, J= 2.0 Hz, 1 H), 4.42 (d, J= 8.0 Hz, 1 H), 4.76 (t, J= 9.2 Hz, 1 H), 4.89 (m, 2 H), 5.11 (d, J= 2.0 Hz, 1 H), 5.34 (d, J= 8.8 Hz, 1 H), 5.64 (d, J= 6.4 Hz, 1 H), 6.13 (t, J= 9.0 Hz, 1 H), 6.94 (d, J= 9.2 Hz, 1 H), 7.06 (dd, J= 9.2, 3.2 Hz, 1 H), 7.29 (d, J= 2.8 Hz 1 H). m/z LC/MS for C58H93NOι6Si2Na+: calcd: 1138.60; found: 1138.43. [96] 15-Hydroxy-4,7,10,13-tetraoxapentadecanoic acid tort-butyl ester (11)- To
300 mL of anhydrous THF was added 80 mg (0.0025 mol) of sodium metal and 128 mL of tetraethylene glycol (0.94 mol) with stirring. After the sodium had completely dissolved, tert-butyl acrylate (24 mL, 0.33 mol) was added. The solution was stirred for 20 hrs at room temperature and neutralized with 8 mL of 1.0 M HC1. The solvent was removed in vacuo and the residue was suspended in brine (250 mL) and extracted with ethyl acetate (3 x 125 mL). The combined organic layers were washed with brine (100 mL) then water (100 mL), dried over sodium sulfate, and the solvent was removed. The resulting colorless oil was dried under vacuum to give 77.13 g (73%) of product. 1H NMR: 1.40 (s, 9H), 2.49 (t, 2 H, J = 6.4 Hz), 3.59 - 3.73 (m, 18 H).
* followed from Seitz and Kunz, J. Org. Chem., 1997, 62, 813-826.
[97] 15-Bromo-4,7,10,13-tetraoxapentadecanoic acid tort-butyl ester (12)- To a stirred solution of 11 (1.0 g, 3.11 mmol) in 1 mL of pyridine at 0° was slowly added phosphorus tribromide (0.116 mL, 1.22 mmol) via syringe. The solution was allowed to stir overnight, at which time the reaction was complete by tic. Water (25 mL) was poured into the reaction vessel and the organics were extracted into methylene chloride (3 x 25 mL). The combined organic layers were washed with sodium bicarbonate (25 mL) then brine (25 mL), dried over magnesium sulfate, and the solvent was removed in vacuo. The residue was purified on silica gel using neat ethyl
acetate as the eluant to give 400 mg (35%) of pure product. 1H NMR: δ 1.37 (s, 9H),
2.43 (t, 2 H, J = 6.4 Hz), 3.40 (t, 2 H, J = 6.4 Hz), 3.53 - 3.61 (m, 12H), 3.64 (t, 2 H, J = 6.4 Hz), 3.74 (t, 2 H, J = 6.4 Hz). 13C NMR: 27.90, 30.13, 36.06, 66.68, 70.17, 70.31, 70.32, 70.39, 70.46, 70.99, 80.22, 170.65.
*modified procedure of Bradshaw et al., J. Het. Chem., 1990, 27, 347-349.
[98] 15-Mercapto-4,7,10,13-tetraoxapentadecanoic acid tort-butyl ester (13)- A flask was charged with Amberlite ion exchange resin _RA-400(O" form) (1.3g, 4.94 mmol of CI") and a solution of NaSH ' H2O (0.218 g, 3.9 mmol) dissolved in 8 mL of
MeOH was added with stirring. After allowing to stir for one hour, at which time the reaction became cloudy, a solution of triethylamine hydrochloride (0.180 g, 1.30 mmol) in 1.5 mL of MeOH was added. A solution of 12 (0.500 g, 1.3 mmol) in 2 mL of MeOH was then added dropwise and allowed to stir at room temperature for 16 hrs.
The resin was then filtered off and 30 mL of 0.5 M HCl was added. The organic layer was separated, and the aqueous layer was extracted into methylene chloride (2 x 25 mL). The combined organic layers were dried over anhydrous sodium sulfate, and the solvent removed in vacuo. The residue was purified on silica gel using neat ethyl acetate as the eluant to give 250 mg (60% yield) of the thiol 13 . 1H NMR: 1.41 (s,
9H), 2.46 (t, 2 H, J = 6.4 Hz), 2.85 (t, 2 H, J = 6.4 Hz), 3.55 - 3.62 (m, 12 H), 3.64 -
3.71 (m, 4 H). I3C NMR: 27.98, 36.14, 38.27, 66.77, 69.51, 70.25, 70.27, 70.39,
70.41, 70.48, 70.52, 80.36, 170.77. MS m/z Calculated: 361.17, Found: 361.94.
[99] 15-(MethyIditio)-4,7,10,13-tetraoxapentadecanoic acid tert-butyl ester
(14)- To a solution of 15-mercapto-4,7,10,13-tetraoxapentadecanoic acid tert-butyl ester (13, 440 mg, 1.30 mmol) in 8 ml of ethanol and 1 ml of NaH2PO (0.5 M, pH 7.0) was added drop wise methylmethanethiosulfonate (368 mg, 2.91 mmol) dissolved in 6 ml of THF. After stirred under Ar over night, the mixture was evaporated to dryness and purified with SiO2 chromatography (2:1 EtOAc/Hexane) to yield 336 mg (67%) of the title compound 14. 1H NMR (CDC13) 3.71 (m, 2H), 3.60 (m, 12H), 2.88 (t, 2H, J = 6.7 Hz), 2.48 (t, 2H, J - 6.1 Hz), 2.40 (s, 3H), 1.43 (s, 9H); MS 407.1 (M+Na)+.
[100] 15-(Methylditio)-4,7,10,13-tetraoxapentadecanoic acid (15)- To a solution of 15-(methylditio)-4,7,10,13-tetraoxapentadecanoic acid tert-butyl ester (14, 335 mg, 0.872 mmol) in 10 ml of dichloromethane was added 1 ml of triethylsilane and 2.0 ml of trifluoroacetic acid. After stirred under Ar over night, the mixture was diluted with 10 ml of toluene and evaporated. The mixture was co-evaporated three times with toluene (3 x 10 ml) to yield 145 mg (51%) of the title compound 15. 'H NMR (CDC13) 3.72 -3.64 (m, 14H), 2.87 (m, 2H), 2.61 (t, 2H, J = 6.1 Hz), 2.40 (s, 3H); MS 351.07 (M+Na)+.
[101] 7-(Triethylsily_)-2'-(triisopropylsi_yIoxy)-3 '-dephenyl-3 '-(isobutenyl)-2- debenzoy_-2-(2,5-dimethoxybenzoyI)-10-(15-methyldithio-4,7,10,13- tetraoxapentadecanoyI)-docetaxel (16)- To a solution of 10 (9 mg, 0.008 mmol) in methylene chloride (0.5 mL) was added DMAP (1 mg), and acid 15 (10 mg, 0.03 mmol, dissolved in 0.5 mL methylene chloride). To this mixture was then added DIC (0.015 mL, 0.08 mmol) and the resulting mixture stiπed overnight. Tic analysis revealed new spot plus a lot of starting material so another 1 mg of DMAP and 0.015 mL of DIC added, and stiπed an additional 2 days. Upon completion, the reaction was quenched with saturated aqueous ammonium chloride (10 mL) and extracted into methylene chloride (10 ml x 3). The combined extracts were dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified on a silica gel column using 50% ethyl acetate in hexane as the eluant to afford the pegylated
product 16 as a white solid (5 mg, 46%): *H NMR (CDCI3) δ 0.56 (m, 6 H), 0.91 (m,
12 H), 1.11 (m, 21 H), 1.20 (s, 3 H), 1.22 (s, 3 H), 1.27 (m, 3 H), 1.38 (s, 9 H), 1.56 (s, 3 H), 1.69 (s, 3 H), 1.72 (s, 6 H), 1.75 (s, 3 H), 1.90 (m, 1 H), 1.99 (s, 3 H), 2.17 (s, 3 H), 2.36 (m, IH), 2.42 (s, 3 H), 2.51 (m, 2 H), 2.74 (m, 2 H), 2.91 (t, J - 6.8 Hz, 2 H), 3.21 (br s, 1 H), 3.66 (m, 12 H), 3.75 (t, J = 6.8 Hz, 2 H), 3.81 (s, 3 H), 3.82 (m, 2 H), 3.97 (s, 3 H), 4.28 (d, J= 8.0 Hz, 1 H), 4.42 (m, 3 H), 4.76 (t, J= 6.4 Hz, 1 H), 4.88 (m, 2 H), 5.35 (d, J= 8.0 Hz, 1 H), 5.67 (d, J= 6.4 Hz, 1 H), 6.07 (t, J= 8.8 Hz, 1 H), 6.46 (s, 1 H), 6.94 (d, J= 9.2 Hz, 1 H), 7.06 (dd, J= 9.2, 3.2 Hz, 1 H), 7.30 (d, J= 2.8 Hz 1 H). m/z LC/MS for C70Hπ5NO2ιSi2S2Na+: calcd: 1148.72; found: 1148.48. [102] 3'-DephenyI-3'-(isobutenyl)-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-10-
(15-methyldithio-4,7,10,13-tetraoxapentadecanoyl)-docetaxel (17)- To a solution of 16 (5 mg, 0.0035 mmol) in pyridine-acetonitrile (1/1, 1.5 mL) was added HF/pyridine (70:30, 0.1 mL) at 0 °C, and the mixture was stiπed for 24 h with warming to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate. The reaction mixture was then diluted with ethyl acetate (5 mL x 2), the combined organic layers were washed with water (5 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified on a silica gel column using neat ethyl acetate as the eluant to afford the final product 17 as
a white solid (2.7 mg, 68%): *H NMR (CDCI3) δ 1.25 (s, 3 H), 1.28 (s, 3 H), 1.38
(s, 9 H), 1.69 (s, 3 H), 1.72 (m, 3 H), 1.75 (s, 3 H), 1.87 (m, 4 H), 2.17 (s, 3 H), 2.35 (m, IH), 2.42 (s, 3 H), 2.54 (m, 2 H), 2.81 (m, 2 H), 2.91 (t, J = 6.8 Hz, 2 H), 3.08 (br s, 1 H), 3.24 (d, J = 6.8 Hz, 1 H), 3.66 (m, 12 H), 3.75 (t, J = 6.8 Hz, 2 H), 3.81 (s, 3 H), 3.82 (m, 2 H), 3.95 (s, 3 H), 4.16 (d, J= 8.8 Hz, 1 H), 4.29 (d, J= 8.0 Hz, 1 H), 4.34 (m, 1 H), 4.41 (d, J= 8.0 Hz, 1 H), 4.72 (m, 2 H), 4.93 (d, J = 8.0 Hz, 1 H), 5.35 (br d, J= 6.0 Hz, 1 H), 5.66 (ά, J= 6.8 Hz, 1 H), 6.16 (t, J- 9.0 Hz, 1 H), 6.32 (s, 1 H), 6.95 (d, J= 9.2 Hz, 1 H), 7.06 (dd, J= 9.2, 3.2 Hz, 1 H), 7.30 (d, J= 2.8 Hz 1 H). m/z LC/MS for C55H8iNO2iS2Na+: calcd: 1178.47; found: 1178.39. [103] 2'-(TriisopropylsiIyoxy)-3'-dephenyl-3'-(isobutenyl)-2-debenzoyl-2-(2,5- dimethoxybenzoyl)-docetaxel (18)- A solution of 5% hydrochloric acid in ethanol
(9.0 mL) was added to 10 (86.4 mg, 0.0774 mmol) at 0 °C. The mixture was stiπed
under N2, with gradual warming to room temperature. After 5 h the reaction was quenched with saturated aqueous sodium bicarbonate and extracted into ethyl acetate (25 mL x 2). The combined ethyl acetate layers were then washed with water (25 mL x 2), dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude residue was purified on a silica gel column with 50% ethyl acetate in hexanes as the
eluant. Product 18 was isolated as a white solid (61.5 mg, 79 %): 1H NMR (CDC13) δ
1.08 (s, 27 H), 1.23 (s, 3H), 1.36 (s, 9 H), 1.58 (m, 1 H), 1.67 (s, 3 H), 1.70 (s, 3 H), 1.76 (s, 3 H), 1.82 (m, 2 H), 1.88 (s, 3 H), 2.16 (s, 3 H), 2.31 (m, 1 H), 2.50 (m, 2 H), 3.17 (br s, 1 H), 3.79 (s, 3 H), 3.85 (d, J= 6.4 Hz, 1 H), 3.95 (s, 1 H), 4.18 (m, 2 H), 4.29 (d, J= 8.4 Hz, 1 H), 4.37 (d, J= 2.0 Hz, 1 H), 4.41 (d, J= 8.4 Hz, 1 H), 4.74 (t, J = 9.0 Hz, 1 H), 4.90 (m, 2 H), 5.17 (d, J= 1.6 Hz, 1 H), 5.32 (d, J= 9.2 Hz, 1 H), 5.65 (d, J= 6.8 Hz, 1 H), 6.10 (t, J= 8.8 Hz, 1 H), 6.93 (d, J= 9.2 Hz, 1 H), 7.05 (dd, J= 9.2, 3.0 Hz, 1 H), 7.28 (d, J= 3.0 Hz, 1 H). m/z LC/MS for C52H79NOι6SiNa+: calcd: 1024.52; found: 1024.31. [104] 2'-(TriisopropylsiIyoxy)- 3'-dephenyl-3'-(isobutenyl)-2-debenzoyl-2-(2,5- dimethoxybenzoyI)-7-(15-methyldithio-4,7,10,13-tetraoxapentadecanoyl)- docetaxel (19)- To a solution of 18 (22.8 mg, 0.0229 mmol), EDC (8.73 mg, 0.0475 mmol) and DMAP (2.79 mg, 0.00229 mmol) in methylene chloride (0.9 mL), a solution of 15 (7.5 mg, 0.0229 mmol) in methylene chloride (0.1 mL) was added. The reaction stiπed under N2 at room temperature overnight. The reaction was quenched with saturated aqueous ammonium chloride and extracted into methylene chloride (25 mL x 2). The combined organic layers were washed with water (15 mL x 1), dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified on a silica gel column with 60 % ethyl acetate in hexanes as the eluant yielding product 19 (9.4 mg, 0.007 mmol) and significant starting material 18 (11.3 mg, 0.0113 mmol). The starting material was redissolved in methylene chloride (0.9 mL) with EDC (4.3 mg, 0.0226 mmol) and DMAP (1.4 mg, 0.0113 mmol). A solution of 15 (3.33 mg, 0.01 mmol) in methylene chloride (0.1 mL) was added and the reaction stiπed under N2 at room temperature for 72 h. Product 19 was extracted and purified as described above and combined with the first fraction (15.3 mg, 51 %): 1H
NMR (CDC13) δ 1.10 (s, 27 H), 1.23 (m, 6 H), 1.37 (s, 9 H), 1.68 (s, 3 H), 1.71 (s, 3
H), 1.87 (s, 3 H), 1.92 (s, 3 H), 2.16 (s, 3 H), 2.33 (m, 2 H), 2.41 (s, 3 H), 2.51 (m, 4 H), 2.89 (t, J= 6.8 Hz, 2 H), 3.20 (br s, 1 H), 3.65 (m, 16 H), 3.74 (t, J= 6.8 Hz, 2 H), 3.80 (s, 3 H), 3.95 (m, 4 H), 4.31 (d, J= 8.0 Hz, 1 H), 4.38 (d, J= 2.0 Hz, 1 H), 4.44 (d, J= 8.4 Hz, 1 H), 4.76 (t, J= 9.4 Hz, 1 H), 4.90 (m, 2 H), 5.28 (s, 1 H), 5.33 (d, J= 8.8 Hz, 1 H), 5.48 (dd, J = 7.2, 10.8 Hz, 1 H), 5.65 (d, J= 6.8 Hz, 1 H), 6.11 (t, J= 9.2 Hz, 1 H), 6.94 (d, J- 9.2 Hz, 1 H), 7.07 (dd, J= 3.2, 9.2 Hz, 1 H), 7.28 (d, J= 3.2 Hz, 1 H). m/z LC/MS for C6 H10ιNO2ιS2SiNa+: cacld: 1334.61; found: 1334.59. [105] 3'-DephenyI-3'-(isobuteny_)-2-debenzoy_-2-(2,5-dimethoxybenzoyl)-7-(15- methyldithio-4,7,10,13-tetraoxapentadecanoyl)-docetaxel (20)- Under N2, 19 (15.3 mg, 0.01166 mmol) was dissolved in pyridine-acetonitrile (1/1, 2.0 mL). HF/pyridine
(70:30, 0.16 mL) was added at 0 °C and the reaction stiπed for 24 h, warming to room
temperature. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted into ethyl acetate (20 mL x 2). The combined organic layers were washed with water (15 mL x 1), dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified on a silica gel column with 80 % ethyl acetate in hexanes as the eluant, yielding 20 (11.8 mg, 87.5 %): 1H NMR
(CDC13) δ 1.24 (s, 6 H), 1.38 (s, 9 H), 1.69 (s, 3 H), 1.74 (s, 3 H), 1.88 (s, 3 H), 1.92
(m, IH), 1.93 (s, 3 H), 2.17 (s, 3 H), 2.32 (m, 2 H), 2.41 (s, 3 H), 2.50 (m, 4 H), 2.9 (t, J= 6.8 Hz, 2 H), 3.10 (br s, 1 H), 3.28 (d, J= 6.4 Hz, 1 H), 3.64 (m, 16 H), 3.72 (t, J = 6.8 Hz, 2 H), 3.80 (s, 3 H), 3.92 (m, 4 H), 4.03 (br s, 1 H), 4.15 (dd, J= 2.0, 6.4 Hz, 1 H), 4.29 (d, J= 8.0 Hz, 1 H), 4.42 (d, J= 8.4 Hz, 1 H), 4.75 (m, 2 H), 4.90 (d, J= 8.0 Hz, 1 H), 5.28 (s, 1 H), 5.33 (br d, J= 8.0 Hz, 1 H), 5.46 (dd, J = 7.2, 10.8 Hz, 1 H), 5.64 (d, J= 6.4 Hz, 1 H), 6.14 (t, J= 8.4 Hz 1 H), 6.94 (d, J= 8.8 Hz, 1 H), 7.06 (dd, J= 3.2, 8.8 Hz, 1 H), 7.29 (d, J= 3.2 Hz, 1 H). m/z LC/MS for C55H8ιNO2ιS2Na+: calcd: 1178.47; found 1178.38.
EXAMPLE 3 CONJUGATION TO ANTIBODIES [106] Conjugation of Thiol-containing PEGylated Taxane to Antibodies via
Disulfide Links- The conjugation of thiol-containing PEGylated taxanes to antibodies, or fragments thereof, via disulfide links is performed in two steps. In the first step dithiopyridyl groups are introduced into antibodies or antibody fragments using succinimidyl pyridyldithiopentanoate (SPP) as described by Carlsson et al. The thiopyridyl groups are then displaced by reaction with the thiol-containing taxane to produce a conjugate.
[107] Preparation of Antibody-SS-PEGylated Taxane Conjugates- Antibodies anti-B4, MY9, anti-EGF receptor and N901, or fragments thereof, are modified with SPDP or SPP as described in the literature. Between 1 to 10 dithiopyridyl groups are introduced on the average per antibody molecule.
[108] A solution of the dithiopyridyl modified antibody at a concentration of 1 mg/ml in 0.1 M potassium phosphate buffer pH 6.5 containing 1 mM EDTA at
25°C is treated with a thiol-containing PEGylated taxane (1.7 molar
equivalent/dithiopyridyl group). The release of thiopyridine from the modified antibody or fragment thereof is monitored spectrophotometrically at 343 nm and is found to be complete in about 20 hours. The antibody-taxane conjugate is purified and freed of unreacted drug and other low molecular weight material by gel filtration through a column of Sephadex G-25. The number of taxane molecules bound per antibody molecule is determined by measuring the ratio between the absorbances at 230 nm and 275 nm. An average of 1-10 taxane molecules per antibody molecule can be linked via disulfide bonds by this method.
[109] Conjugation of Thiol-Containing PRGylated Taxane to Antibodies via a
Noncleavable Thioether Link- The conjugation of a thiol-containing PEGylated- taxane is performed in two steps. The antibody, or fragment thereof, is first reacted with succinimidyl maleimidomethylcyclohexane carboxylate (SMCC) to introduce maleimido groups. The modified antibody is then reacted with the thiol-containing PEGylated taxane forming thioether links. [110] Preparation of Antibody-PEGylated Taxane Conjugates (non-cleavable)-
Antibodies, anti-B4, MY9, anti-EGF receptor and N901, or fragments thereof, are modified with SMCC as described in the literature. [Ill] The modified antibodies or antibody fragments are treated with thiol-containing taxane (1.25 molar equivalent/maleimido group). The mixtures are
incubated overnight at 4°C. The antibody-taxane conjugates are purified as described
above. Typically, an average of 1-10 taxane molecules per antibody molecule are linked.
EXAMPLE 4 j_
OTHER METHODS OF LINKING PEGY1ATED TAXANES Acid Labile Linkers
[112] PEGylated Taxanes can be esterified with N-protected amino acids, such as
N-tboc-L-alanine in the presence of dicyclohexyl-carbodiimide and dimethylaminopyridine (DMAP) by standard methods described in the chemical literature. Cleavage of the t-boc protecting group with trifluoroacetic acid will give a taxane ester containing a terminal amino group. This amino group containing taxane can be linked to antibodies, or fragments thereof, and other cell binding agents via an acid labile linker as previously described (Bla tler et al, 24 Biochemistry, 1517-1524
(1985), U.S. Patent Nos. 4,542,225, 4,569,789 and 4,764,368).
Photolabile Linker [113] The amino group-containing PEGylated taxane derivative described above can be linked to cell binding agents via a photolabile linker as previously described.
(Senter et al, 42 Photochemistry and Photobiology, 231-237 (1985), U.S. Patent
4,625,014). Peptidase Labile Linker
[114] The amino group-containing PEGylated taxane described above can also be linked to cell binding agents via peptide spacer linkers. It has been previously shown that short peptide spacers between drugs and macromolecular protein carriers are stable in serum but are readily hydrolyzed by intracellular lysosomal peptidases
(Trouet et al, 79 Proc. Natl Acad. Sci., 626-629 (1982)). The amino group containing taxane can be condensed with peptides such as Ala-Leu, Leu-Ala-Leu or a dimer of Ala-Leu using condensing agents such as l-[3-(dimethylamino)propyl]-3- ethyl carbodiimide-HCl to give a peptide derivative of the taxane which can then be linked to cell binding agents.
Esterase Labile Linker [115] PEGylated Taxanes can be esterified by reaction of the hydroxyl group with succinic anhydride and then linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free drug. (For examples see:
Aboud-Pirak et al, 38 Biochem. Pharmacol., 641-648 (1989), Laguzza et al, 32 J.
Med. Chem., 549-555 (1989)).

Claims

WHAT IS CLAIMED IS:
1. A taxane comprising a polyethylene glycol-containing linking group at C-7 or C-10*
2. The taxane of claim 1, wherein the polyethylene glycol-containing linking group comprises a thiol or disulfide as a linking moiety.
3. The taxane of claim 2, wherein the polyethylene glycol-containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
4. The taxane of claim 1 , wherein the polyethylene glycol-containing linking group is cleavable.
5. The taxane of claim 1, wherein the polyethylene glycol-containing linking group is acid labile, photolabile, peptidase labile, or esterase labile.
6. The taxane of claim 1 , wherein the polyethylene glycol-containing linking group is not cleavable.
7. The taxane of claim 1 , wherein the substituent comprising the polyethylene glycol- containing linking group is selected from the group consisting of: -(CR,3R14),(CH2)m(C R,3Ri4)1(OCH2CH2)„O(C R.3R.4XCH2MC Rι3 i4)ιSZ,
-CO(C R13R14),(CH2)m(C n i4)ι (OCH2CH2)nO(C Rι3R,4),(CH2)m(C Rι3R,4), SZ,
-CONR,2(C R,3R,4)ι(CH2)m(C R,3R,4),(OCH2CH2)„O(C Rι3R,4),(CH2)m(CR,3Rι4)ι SZ,
-(CR13R,4),(CH2)m(CRi3Ri4)ι(OCH2CH2)nOCO(CR,3Rι4),(CH2)m(CRι3Ri4)ιSZ,
-(CR,3R14)1(CH2)m(CR13R14).(OCH2CH2)nNR12CO(CR13Ri4)I(CH2)m(CR13R14)ιSZ,
-(CR,3R,4),(CH2)m(CR13R14)1(OCH2CH2)nOCONR12(CRι3R14)1(CH2)m(CR13R14)ιSZ,
-CO(CRι3Ri4)ι(CH2)m(CR13R14)1 (OCH2CH2)nOCO(CRι3R,4)1(CH2)m(CRι3R,4)1 SZ,
-CO(CR13R14)1(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14)1(CH2)m(CR13Rι4)1 SZ,
-CO(CR13R14).(CH2)m(CR13R14)1(OCH2CH2)nOCONRl2(CR13R14)1(CH2)m(CR13R14)1 SZ,
-CONRn^RπRHXC^^CRπRπXόCHzCHz^OCO^R^Rj^ CH^^CRnRu)^^
-CONR12(CR13R,4)1(CH2)m(CR13Rl4)1(OCH2CH2)nNR12CO(CR,3R14)1(CH2)m(CRι3R,4)ι SZ, -CONR12(CR,3R,4)ι(CH2)m(CR13RI4)1(OCH2CH2)πOCONR12(CR13R14)1(CH2)m(CR,3Rι4). SZ,
-CO-mo holino-X(OCH2CH2)nSZ, -CO-piperazino-X(OCH2CH2)nSZ, -CO-piperidino- X(OCH2CH2)nSZ, and -CO-N-methylpiperazino-X(OCH2CH2)nSZ, wherein
Z is H or SR,
X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
R and Rj2 are the same or different and represent linear alkyl, branched alkyl or cyclic • alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H,
R13 and R14 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl,
1 is 0 or an integer from 1 to 10,
m is an integer of 1 to 10, and
n is 2 to 1000.
8. A compound of formula (I):
Figure imgf000043_0001
(I) wherein:
Ri is H, an electron withdrawing group, or an electron donating group; Ri1 and Ri" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is -(CR13Ri4)ι(CH2)m(C R13R14),(OCH2CH2)nO(C Rι3Ri4)ι(CH2)m(C Rl3Rι )ιSZ,
-CO(C R13R14),(CH2)m(C R,3R14), (OCH2CH2)nO(C R13R14)ι(CH2)m(C RI3RM)I SZ,
-CONRι2(C R13Rι4)1(CH2)m(C R13R14)ι(OCH2CH2)nO(C R13Ri4)ι(CH2)m(CR13R14)ι SZ, -(CR13R14).(CH2)m(CR13Ri4)1(OCH2CH2)nOCO(CR13R14)1(CH2)m(CR13Ri4)ιSZ,
-(CR13R14),(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14).(CH2)m(CR13R14)1SZ,
-(CR13R14),(CH2)m(CR13R14)1(OCH2CH2)nOCONR12(CR13R14)1(CH2)m(CR13R14)1SZ,
-CO(CR13R14)1(CH2)m(CR13R14)1 (OCH2CH2)nOCO(CR13R14)1(CH2)m(CR13R14), SZ,
-CO(CR13R14),(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14)1(CH2)m(CR13R14)1 SZ,
-CO(CR13R14)1(CH2)m(CR13R14)I(OCH2CH2)„OCONR12(CR13R14),(CH2)m(CR13Ri4)ι SZ,
-CONR12(CR13Ri4)1(CH2)m(CR13R14)1(OCH2CH2)nOCO(CR13R14)1(CH2)m(CR,3Ri4). SZ, -CONRι2(CR13R14)ι(CH2)m(CR13R14)ι(OCH2CH2)nNR12CO(CR13Ri4)ι(CH2)m(CRι3R14)ι SZ,
-CONR12(CRi3Ri4)ι(CH2)m(CRι3R14)1(OCH2CH2)nOCONR12(CRι3R14)1(CH2)m(CR13R14)1 SZ,
-CO-moφholino-X(OCH2CH2)nSZ, -CO-piperazino-X(OCH2CH2)nSZ, -CO-piperidino-
X(OCH2CH2)nSZ, and -CO-N-methylpiperazino-X(OCH2CH2)nSZ, wherein
Z is H or SR,
X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
R and Rι2 are the same or different and represent linear alkyl, branched alkyl or cyclic
alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H,
R) and Rι are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl,
1 is 0 or an integer from 1 to 10, m is an integer of 1 to 10, and
n is 2 to 1000;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R_t is -OC(CH3)3 or -C6H5; and
R5 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of formula -CNRioRn, wherein Rio and Rn are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms.
9. A compound of formula (I) :
Figure imgf000045_0001
(I) wherein:
Ri is H, an electron withdrawing group, or an electron donating group;
Ri1 and Ri" are the same or different and are H, an electron withdrawing group, or an electron donating group;
R2 is H, a heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula -CNRioRn, wherein Rio and Rn are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms;
R3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms;
R is -OC(CH3)3 or -C6H5; and
R5 is -(CR,3R,4),(CH2)m(C Rι3Rι4)1(OCH2CH2)nO(C R13R,4),(CH2)m(C Rι3R.4)ιSZ, -CO(C R13R,4),(CH2)m(C Rι3Ri4)ι (OCH2CH2)nO(C Rι3Rι4)ι(CH2)m(C Rι3R,4), SZ, -CONR,2(C R,3R,4),(CH2)m(C Rι3R,4),(OCH2CH2)nO(C R,3R,4),(CH2)m(CRι3R,4)1 SZ, -(CRι3Rι4)ι(CH2)m(CRι3Rι4)1(OCH2CH2)nOCO(CRι3Rι4)1(CH2)m(CRι3Ri4).SZ, -(CRι3R14)ι(CH2)m(CRι3Ri4)1(OCH2CH2)nNRι2CO(CR,3Rι4),(CH2)m(CRι3Rι4)1SZ, -(CRι3Ri4)ι(CH2)m(CRι3Rι4)1(OCH2CH2)nOCONR12(CRι3Ri4)1(CH2)m(CRι3R,4)1SZ, -CO(CR13Rι )ι(CH2)m(CRι3Rι4)1 (OCH2CH2)nOCO(CRι3Rι4),(CH2)m(CRι3Rι4), SZ, -CO(CRι3Rι4),(CH2)m(CRi3Rι )1(OCH2CH2)nNRι2CO(CRi3Ri4)1(CH2)m(CR,3Ri4)ι SZ, -CO(CR,3Ri4)ι(CH2)m(CR,3Ri4)ι(OCH2CH2)nOCONR,2(CR,3R14),(CH2)m(CRι3R14)1 SZ, -CONRι2(CR13Rι4)1(CH2)m(CRι3R,4)l(OCH2CH2)nOCO(CRι3R,4)1(CH2)m(CRι3R14)1 SZ, -CONR,2(CR,3Ri4)1(CH2)m(CRι3R,4)1(OCH2CH2)nNR,2CO(CRι3R,4)ι(CH2)m(CRι3Ri4)ι SZ, -CONRi2(CRι3R,4),(CH2)m(CRι3R14)1(OCH2CH2)nOCONR,2(CRι3Rι4),(CH2)m(CRι3Rι4), SZ, -CO-moφholino-X(OCH2CH2)nSZ, -CO-piρerazino-X(OCH2CH2)nSZ, -CO-piρeridino- X(OCH2CH2)nSZ, and -CO-N-methylpiperazino-X(OCH2CH2)nSZ, wherein
Z is H or SR,
X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
R and Rj2 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and Rι2 can in addition be H,
Rι3 and Rι4 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl,
1 is 0 or an integer from 1 to 10,
m is an integer of 1 to 10, and
n is 2 to 1000.
10. The compound of claim 8 or 9, wherein Ri is H, F, NO2, CN, CI, CHF2, CF3) - OCH3, -OCH2CH3, -NRβRy, or -ORs.
11. The compound of claim 8 or 9, wherein Ri is OMe, OEt, CI, F, NO2, or CF3.
12. The compound of claim 8 or 9, wherein R\ is in the meta position, Ri' is OMe,
Figure imgf000047_0001
13. The compound of claim 8 or 9, wherein Ri' and Ri" are the same or different and are H, F, NO2, CN, CI, CHF2, CF3, -OCH3, OCH2CH3, -NR^R-z, or -ORs, wherein:
R$ and R7 are the same or different and are each H, linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms, and Rs is linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
14. The compound of claim 13, wherein R^ and R7 are same or different and are each H, or are alkyl or aryl having 1 to 4 carbon atoms.
15. The compound of claim 13, wherein -NR$R7 is dimethyl amino, diethyl amino, dipropyl amino, or dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl..
16. The compound of claim 8 or 9, wherein R3 is -CH2CH(CH3)2 or -CH=C(CH3)2.
17. The compound of claim 8 or 9, wherein R4 is -OC(CH )3 or -C6H5.
18. The compound of claim 8, wherein R5 is H, -COCH3, -COCH2CH3 and -COCH2CH2CH3.
19. The compound of claim 9, wherein R2 is H, -COCH3, -COCH2CH3 and -COCH2CH2CH3.
20. The compound of claim 8, wherein R5 is H, or -CONHCH2CH3> - CONHCH2CH2CH3, -CO-moφholino, -CO-piperazino, -CO-piperidino, or -CO-N- methylpiperazino .
21. The compound of claim 9, wherein R2 is H, or -COΝHCH2CH3, - CONHCH2CH2CH3, -CO-moφholino, -CO-piperazino, -CO-piperidino, or -CO-N- methylpiperazino.
22. A cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes.
23. The cytotoxic agent of claim 22, wherein the polyethylene glycol-containing linking group comprises a thiol or disulfide as the linking moiety.
24. The cytotoxic agent of claim 22, wherein the polyethylene glycol-containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
25. The cytotoxic agent of claim 22, wherein at least one of the taxanes is linked to the cell binding agent through a cleavable linking group.
26. The cytotoxic agent of claim 25, wherein the cleavable linking group is acid labile, photolabile, peptidase labile or esterase labile.
27. The cytotoxic agent of claim 22, wherein at least one of the taxanes is linked to the cell binding agent through a non-cleavable linking group.
28. The cytotoxic agent of claim 22, wherein the substituent comprising the polyethylene glycol-containing linking group is selected from the group consisting of: -(CR,3R,4),(CH2)m(C R,3R,4)ι(OCH2CH2)nO(C R13Ri4)ι(CH2)m(C RI3Rι ).SZ,
-CO(C R13Rι4)ι(CH2)m(C R13R14), (OCH2CH2)nO(C R,3Rι4)ι(CH2)m(C R,3Rι4). SZ,
-CONR,2(C R13Rι4)ι(CH2)m(C Rι3Rι4),(OCH2CH2)nO(C Rι3R14)ι(CH2)m(CR,3Ri4)ι SZ, -(CRi3Ri4)1(CH2)rn(CR,3Ri4)i(OCH2CH2)nOCO(CRi3Ri4)1(CH2)m(CR13R,4)1SZ, -(CR,3R,4)1(CH2)m(CRι3Rι4)1(OCH2CH2)nNR12CO(CR13R,4)1(CH2)m(CR,3R14)ιSZ,
-(CR13R14)1(CH2)m(CR13R14)1(OCH2CH2)nOCONR12(CRi3Ri4)ι(CH2)m(CR13R14),SZ,
-CO(CR13R14),(CH2)m(CR13R14)1 (OCH2CH2)nOCO(CR13R14)1(CH2)m(CRi3Ri4)ι SZ,
-CO(CR13R14)1(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14)ι(CH2)m(CR13R14)1 SZ,
-CO(CR13R14),(CH2)m(CR13R14)1(OCH2CH2)nOCONR12(CR13R14),(CH2)m(CR13Rι4), SZ,
-CONR12(CR13R14)1(CH2)m(CRι3Ri4)ι(OCH2CH2)nOCO(CR13R14),(CH2)m(CR13R14), SZ,
-CONR12(CR13R14)ι(CH2)m(CR13R14)1(OCH2CH2)nNR12CO(CR13R14)1(CH2)m(CR13Rι4)1 SZ,
-CONR12(CR13Rι4)1(CH2)m(CR13R14),(OCH2CH2)nOCONR12(CR13R14)1(CH2)m(CR13R14), SZ,
-CO-moφhoUno-X(OCH2CH2)nSZ, -CO-piρerazino-X(OCH2CH2)nSZ, -CO-piperidino-
X(OCH2CH2)nSZ, and -CO-N-methylpiperazino-X(OCH2CH2)nSZ, wherein
Z is H or SR,
X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
R and Rι2 are the same or different and represent linear alkyl, branched alkyl or cyclic
alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms
or heterocyclic, and R12 can in addition be H,
Ri3 and R14 are same or different and represent H or linear alkyl, branched alkyl or
cyclic alkyl having 1 to 10 carbon atoms, or aryl,
1 is 0 or an integer from 1 to 10,
m is an integer of 1 to 10, and n is 2 to 1000.
29. The cytotoxic agent of claim 22, wherein the cell binding agent is an antibody or an antibody fragment.
30. The cytotoxic agent of claim 22, wherein the cell binding agent is an antibody, a single chain antibody or a binding fragment of an antibody or single chain antibody.
31. The cytotoxic agent of claim 22, wherein the cell binding agent is a monoclonal antibody, a single chain monoclonal antibody or a binding fragment of a single chain monoclonal antibody a monoclonal antibody which is or is not humanized or resurfaced or chimeric.
32. The cytotoxic agent of claim 31 , wherein the cell binding agent binds specifically to the CD33 antigen.
33. The cytotoxic agent of claim 31 , wherein the cell binding agent binds specially to the CD56 antigen.
34. The cytotoxic agent of claim 22, wherein the cell binding agent is an interferon, a lymphokine, a hormone, a vitamin, a growth factor, a colony-stimulating factor, or transferrin.
35. The cytotoxic agent of claim 22, wherein the cell binding agent is epidermal growth factor, transforming growth factor, vascular endothehal growth factor, fibroblast growth factor, insulin like growth factor 1 and 2, platelet derived growth factor,melanocyte stimulating hormone, thyroid stimulating hormone, somatostatin, estrogen, estrogen analogue, androgen, androgen analogue, or folate.
36. A therapeutic composition comprising:
(A) An effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent through a polyethylene glycol-containing linking group at C-7 or C-10 of at least one of the taxanes; and
(B) A pharmaceutically acceptable carrier, diluent, or excipient.
37. The therapeutic composition of claim 36, wherein the polyethylene glycol- containing linking group comprises a thiol or disulfide as the linking moiety.
38. The therapeutic composition of claim 36, wherein the polyethylene glycol- containing linking group is carried on a side chain that is a linear or branched, aromatic or heterocyclic group.
39. The therapeutic composition of claim 36, wherein at least one of the taxanes is linked to the cell binding agent through a cleavable linking group.
40. The therapeutic composition of claim 39, wherein the cleavable linking group is acid labile, photolabile, peptidase labile or esterase labile.
41. The therapeutic composition of claim 36, wherein at least one of the taxanes is linked to the cell binding agent through a non-cleavable linking group.
42. The therapeutic composition of claim 36, wherein the substituent comprising the polyethylene glycol-containing linking group is selected from the group consisting of: -(CR13R14),(CH2)m(C R13R14),(OCH2CH2)nO(C R13Rι ).(CH2)m(C Rι3R14)ιSZ,
-CO(C Rι3R14),(CH2)m(C R13R14), (OCH2CH2)nO(C R13R14),(CH2)m(C R13R14), SZ,
-CONR12(C R13R14),(CH2)m(C R13R14),(OCH2CH2)nO(C R13R14),(CH2)m(CR13Rι4)1 SZ,
-(CRι3R14)1(CH2)m(CR13R14)1(OCH2CH2)nOCO(CR13Rι )ι(CH2)m(CRι3Ri4).SZ,
-(CR,3Ri4)ι(CH2)m(CR13Ri4)ι(OCH2CH2)nNR12CO(CR13R14)ι(CH2)m(CR13Rι4)ιSZ,
-(CR13Ri4).(CH2)m(CR13R14)ι(OCH2CH2)nOCONR12(CRι3R14),(CH2)nι(CR13R1 )ιSZ,
-CO(CR13R14)1(CH2)m(CR13R14)1 (OCH2CH2)nOCO(CR13RH)ι(CH2)„1(CR13R14)1 SZ,
-CO(CR13R14),(CH2)m(CR13Rι4)1(OCH2CH2)nNR12CO(CR13Rι4)ι(CH2)m(CR13Rι4)ι SZ,
-CO(CR13Rι4).(CH2)m(CR,3Rι4)1(OCH2CH2)nOCONR12(CR,3Ri4)ι(CH2)m(CR13Rt4)ι SZ,
-CONRn^RπRHWCHz CRπRi^^OCHzCH^nOCO^RnRuXCHj CRπRH)^^
-CONRn^RπRi^ CH^^CRBRπXOCHzCH^nNR^CO^RnRHXCHz CRπRM^ SZ,
-CONR12(CR13R14)ι(CH2)m(CR13Rι4)1(OCH2CH2)nOCONR12(CR13R,4)1(CH2)m(CR13Rι )ι SZ, -CO-moφholino-X(OCH2CH2)nSZ, -CO-ρiperazino-X(OCH2CH2)nSZ, -CO-piperidino- X(OCH2CH2)nSZ, and -CO-N-methylpiperazino-X(OCH2CH2)nSZ, wherein Z is H or SR,
X is a linear alkyl or branched alkyl having 1-10 carbon atoms,
R and Rι2 are the same or different and represent linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having 1 to 10 carbon atoms or heterocyclic, and R12 can in addition be H,
Rι.3 and Rι4 are same or different and represent H or linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or aryl,
1 is 0 or an integer from 1 to 10,
m is an integer of 1 to 10, and
n is 2 to 1000.
43. The therapeutic composition of claim 36 or 37, wherein the cell binding agent is an antibody or an antibody fragment.
44. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is an antibody, a single chain antibody or a binding fragment of an antibody or single chain antibody.
45. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is a monoclonal antibody, a single chain monoclonal antibody or a binding fragment of a single chain monoclonal antibody a monoclonal antibody which is or is not humanized or resurfaced or chimeric?.
46. The therapeutic composition of claim 45, wherein the cell binding agent binds specifically to the CD33 antigen.
47. The therapeutic composition of claim 45, wherein the cell binding agent binds specifically to the CD 19 antigen.
48. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is an interferon, a lymphokine, a hormone, a vitamin, a growth factor, a colony-stimulating factor, or transferrin.
49. The therapeutic composition of any one of claims 36, 37, 38 or 42, wherein the cell binding agent is epidermal growth factor, , transforming growth factor, vascular endothehal growth factor, fibroblast growth factor, insulin like growth factor 1 and 2, platelet derived growth factor, somatostatin, melanocyte stimulating hormone, thyroid stimulating hormone, estrogen, estrogen analogue, androgen, androgen analogue, or folate.
50. A method of killing selected cell populations comprising contacting target cells or tissue containing target cells with a cytotoxic amount of the cytotoxic agent of any one of claims 22 to 35.
PCT/US2003/002675 2002-05-14 2003-02-11 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use WO2003097625A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003210731A AU2003210731C1 (en) 2002-05-14 2003-02-11 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CA2485424A CA2485424C (en) 2002-05-14 2003-02-11 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP2004505358A JP2005533026A (en) 2002-05-14 2003-02-11 Cytotoxic agent containing taxane containing polyethylene glycol and therapeutic use thereof
EP03752980A EP1506181A4 (en) 2002-05-14 2003-02-11 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/144,042 US6596757B1 (en) 2002-05-14 2002-05-14 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US10/144,042 2002-05-14

Publications (1)

Publication Number Publication Date
WO2003097625A1 true WO2003097625A1 (en) 2003-11-27

Family

ID=22506806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002675 WO2003097625A1 (en) 2002-05-14 2003-02-11 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Country Status (6)

Country Link
US (1) US6596757B1 (en)
EP (1) EP1506181A4 (en)
JP (2) JP2005533026A (en)
AU (1) AU2003210731C1 (en)
CA (1) CA2485424C (en)
WO (1) WO2003097625A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534674A2 (en) * 2002-08-02 2005-06-01 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
WO2006061259A2 (en) * 2004-12-07 2006-06-15 Aventis Pharma S.A. Cytotoxic agents comprising new c-2 modified taxanes
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7494649B2 (en) 2003-05-14 2009-02-24 Immunogen, Inc. Drug conjugate composition
EP2241577A1 (en) 2007-08-09 2010-10-20 Boehringer Ingelheim International GmbH Anti-CD37 antibodies
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
US9114179B2 (en) 2005-08-03 2015-08-25 Immunogen, Inc. Immunoconjugate formulations
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DE60234094D1 (en) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd SPECIFIC TIE PROTEINS AND ITS USE
US7910594B2 (en) * 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2517730A3 (en) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
CN101098854B (en) 2004-07-23 2012-12-05 恩多塞特公司 Bivalent linkers and conjugates thereof
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
RU2375384C2 (en) 2004-09-22 2009-12-10 Ниппон Каяку Кабусики Кайся New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
CN101175757B (en) * 2005-03-16 2012-11-14 恩多塞特公司 Synthesis and purification of pteroic acid and conjugates thereof
EP1948240A2 (en) * 2005-08-19 2008-07-30 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs and derivatives
CN103893779A (en) 2005-08-19 2014-07-02 恩多塞特公司 Multi-drug ligand conjugates
CA3190867A1 (en) 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US8323669B2 (en) * 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
BRPI0714871A2 (en) 2006-07-18 2013-05-07 Sanofi Aventis antagonist antibody for cancer treatment
JP5548364B2 (en) * 2006-10-03 2014-07-16 日本化薬株式会社 Polymer conjugates of resorcinol derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
CN104013956B (en) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) * 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
MX2010001757A (en) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
CN101945892B (en) * 2007-12-26 2017-11-24 生物测试股份公司 For the method and reagent of the targeting for improving the tumour cell to expressing CD138
CA2710453C (en) 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
CA2710471C (en) * 2007-12-26 2018-06-05 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
EP2258397B1 (en) * 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
CN102083461B (en) * 2008-04-30 2014-09-17 伊缪诺金公司 Potent conjugates and hydrophilic linkers
KR101764081B1 (en) 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 Cross-linkers and their uses
WO2009136572A1 (en) 2008-05-08 2009-11-12 日本化薬株式会社 Polymer conjugate of folic acid or folic acid derivative
CN102421827B (en) 2009-05-15 2014-07-30 日本化药株式会社 Polymer conjugate of bioactive substance having hydroxy group
KR102560218B1 (en) 2009-06-03 2023-07-26 이뮤노젠 아이엔씨 Conjugation methods
US8470980B2 (en) * 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
WO2012067138A1 (en) 2010-11-17 2012-05-24 日本化薬株式会社 Novel polymer derivative of cytidine metabolism antagonist
RU2013127786A (en) * 2010-11-19 2014-12-27 Венус Ремедиз Лимитед NEW CONJUGATES FOR DIRECTED DRUG DELIVERY
EA201991268A3 (en) 2011-03-29 2020-01-31 Иммуноджен, Инк. OBTAINING MAYTANSINOID-ANTIBODIES CONJUGATES IN ONE-STEP METHOD
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
UA115402C2 (en) 2011-05-21 2017-10-25 Макродженікс, Інк. CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
KR101972303B1 (en) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
WO2013035641A1 (en) 2011-09-11 2013-03-14 日本化薬株式会社 Method for manufacturing block copolymer
MX358680B (en) 2011-12-08 2018-08-31 Biotest Ag Uses of immunoconjugates targeting cd138.
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
SG11201502896XA (en) 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
JP6133431B2 (en) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
KR102087850B1 (en) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
SG11201606714TA (en) 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
PT3122757T (en) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Charged linkers and their uses for conjugation
CN113350518A (en) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 Conjugated bridge linkers to cell binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
CN116143678A (en) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN111315414A (en) 2017-06-22 2020-06-19 梅尔莎纳医疗公司 Methods of producing drug-loaded polymer scaffolds and protein-polymer-drug conjugates
SG11202007495SA (en) 2018-02-21 2020-09-29 Celgene Corp Bcma-binding antibodies and uses thereof
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
BR112022013255A2 (en) 2020-01-09 2022-09-06 Mersana Therapeutics Inc SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING BINDERS
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648506A (en) * 1992-06-04 1997-07-15 Vivorx, Inc. Water-soluble polymeric carriers for drug delivery
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547981A (en) * 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
NZ517772A (en) * 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
WO2001074399A1 (en) * 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Drugs retained in target tissue over long time

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648506A (en) * 1992-06-04 1997-07-15 Vivorx, Inc. Water-soluble polymeric carriers for drug delivery
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7495114B2 (en) 2002-08-02 2009-02-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1534674A2 (en) * 2002-08-02 2005-06-01 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7414073B2 (en) 2002-08-02 2008-08-19 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1534674A4 (en) * 2002-08-02 2007-11-28 Immunogen Inc Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8012485B2 (en) 2003-05-14 2011-09-06 Immunogen, Inc. Drug conjugate composition
US7514080B2 (en) 2003-05-14 2009-04-07 Immunogen, Inc. Drug conjugate composition
US7501120B2 (en) 2003-05-14 2009-03-10 Immunogen, Inc. Drug conjugate composition
US7494649B2 (en) 2003-05-14 2009-02-24 Immunogen, Inc. Drug conjugate composition
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
WO2005079861A3 (en) * 2004-02-13 2007-03-15 Safeway Invest Ltd Polymeric water soluble prodrugs
WO2006061259A3 (en) * 2004-12-07 2007-01-11 Aventis Pharma Sa Cytotoxic agents comprising new c-2 modified taxanes
US7667054B2 (en) 2004-12-07 2010-02-23 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
AU2005313444B2 (en) * 2004-12-07 2011-11-10 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
WO2006061258A3 (en) * 2004-12-07 2006-09-28 Aventis Pharma Sa Cytotoxic agents comprising new taxanes
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
WO2006061259A2 (en) * 2004-12-07 2006-06-15 Aventis Pharma S.A. Cytotoxic agents comprising new c-2 modified taxanes
WO2006061258A2 (en) * 2004-12-07 2006-06-15 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US7598290B2 (en) 2004-12-07 2009-10-06 Immunogen, Inc. Cytotoxic agents comprising new C-2 modified taxanes
EA012625B1 (en) * 2004-12-07 2009-10-30 Авентис Фарма С.А. Cytotoxic agents comprising new taxanes
JP2008523019A (en) * 2004-12-07 2008-07-03 アバンテイス・フアルマ・エス・アー New cytotoxic drugs containing taxanes
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US9114179B2 (en) 2005-08-03 2015-08-25 Immunogen, Inc. Immunoconjugate formulations
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP2241577A1 (en) 2007-08-09 2010-10-20 Boehringer Ingelheim International GmbH Anti-CD37 antibodies
EP2562187A1 (en) 2007-08-09 2013-02-27 Boehringer Ingelheim International GmbH Anti-CD37 antibodies
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods
WO2022058548A1 (en) 2020-09-17 2022-03-24 Merck Patent Gmbh Molecules with solubility tag and related methods

Also Published As

Publication number Publication date
CA2485424C (en) 2010-12-14
AU2003210731B8 (en) 2009-06-25
JP2011042679A (en) 2011-03-03
EP1506181A4 (en) 2006-11-08
US6596757B1 (en) 2003-07-22
CA2485424A1 (en) 2003-11-27
JP2005533026A (en) 2005-11-04
EP1506181A1 (en) 2005-02-16
AU2003210731B2 (en) 2009-06-11
AU2003210731A1 (en) 2003-12-02
AU2003210731C1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
US6596757B1 (en) Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7414073B2 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1242401B1 (en) Cytotoxic agents comprising taxanes and their therapeutic use
US7390898B2 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003210731

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2485424

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003752980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004505358

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003752980

Country of ref document: EP